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Objective: Xerostomia is a substantial problem for a majority of patients in palliative 
care. Guidelines that exist for palliative care are mainly based on tradition and long-
time experience. Scientific evidence is sparse. Consequently, one of the agents used 
for lubrication, glycerol, is recommended in some countries, while not recommended 
in others. Presently, little is known about the effects of different procedures for oral 
palliative care. 
Aim: The overall aim was to study procedures and oral care products with the 
aspiration of contributing in some measure to the body of knowledge within the field 
of oral palliative care and its future guidelines.  
Material and methods: A questionnaire study was conducted to explore 
circumstances surrounding procedures and knowledge regarding oral palliative care 
in Norwegian healthcare institutions. An in vitro study on reconstructed human oral 
mucosa was used to explore biological, dose-dependent effects of glycerol. Finally, 
the effectiveness of three different oral moisturizers were compared in a randomized 
controlled trial (RCT) in palliative care patients suffering from xerostomia. 
Results: The questionnaire study revealed that a plethora of different procedures for 
oral palliative care exist and that 25 % do not have oral palliative care procedures at 
all. The laboratory study showed that glycerol in concentrations of 42.5% and over 
led to an increase in cell proliferation and apoptosis, but had no effect on tissue 
integrity. In the RCT, 17% glycerol had the best effect directly after application, but 
no effect after two hours. The two other products had long-lasting effect, but were not 
preferred by the patients. 
Conclusions: There is an obvious need for awareness about a standardisation of oral 
palliative care. Glycerol does not seem to harm the mucosa in low concentrations, but 
lacks long-term effect. Other products may be more effective, but taste and 
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1.1 General background 
The majority of seriously ill and dying patients have problems with xerostomia, the 
subjective feeling of dry mouth (1, 2). The dry mouth problem may be caused by 
medication, treatments or as a direct result of the mortal condition (3-5). This 
condition can lead to oral pain, dysphagia, speech disturbances, loss of appetite, 
dehydration and malnutrition, thus affecting the disease negatively and contributing 
to reduced quality of life (6-9).  Until now, there is no strong evidence that any 
topical therapy is effective in relieving the symptom of dry mouth (10). In 2017 82% 
of deaths in Norway occurred in an institution: 32% in hospitals and 50% in nursing 
homes (11).  
1.2 Definition of palliative care 
Palliative medicine is the term used for the medical specialty area, whereas Palliative 
Care is used for the field as a whole (12). When palliative medicine was approved as 
a specialty in the United Kingdom in 1987, a definition was made specifically aimed 
for medicine: “Palliative medicine is the study and management of patients with 
active, progressive, far advanced disease, for whom the prognosis is limited and the 
focus of care is quality of life” (13). The term terminal is often imprecisely used 
synonymously with palliative, but primarily the term terminal describes the last few 
hours or days before death (14). 
Several definitions for palliative care have been proposed. The first WHO definition, 
from 1990, emphasized its relevance to patients who did not respond to curative 
therapy (15). This statement could be interpreted as relegating palliative care to the 
last stages of care:  
“Palliative care is the active, total care of patients with progressive, far advanced 
disease and limited life expectancy whose disease is not responsive to curative 
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treatment. It refers to the control of pain and of other symptoms as well as the 
treatment of social, psychological, and spiritual problems”. (WHO, 1990) (15). 
Today, there is a wider recognition that the principles of palliative care should be 
applied as early as possible in the course of any chronic, ultimately fatal illness (16):  
“Palliative care is an approach that improves the quality of life of patients and their 
families facing the problem associated with life-threatening illness, through the 
prevention and relief of suffering by means of early identification and impeccable 
assessment and treatment of pain and other problems, physical, psychosocial, and 
spiritual”. (WHO, 2002) (17).  
WHO's latest definition has gradually become quite widespread, but it describes 
palliative care as an approach. The European Association for Palliative Care (EAPC) 
sees palliative care not only as an approach, but also as a discipline in its own right. 
That is probably one of the reasons why EAPC has a definition of palliative care 
much like the first WHO definition (18). 
International Association for Hospice and Palliative Care (IAHPC) has just developed 
a new (2018) definition of palliative care that is receiving broad support:  
“Palliative care is the active holistic care of individuals across all ages with serious 
health-related suffering due to severe illness, and especially of those near the end of 
life. It aims to improve the quality of life of patients, their families and their 
caregivers” (19).  
1.3 History of palliative care  
Until the end of the 19th century, healthcare services consisted primarily of care and 
relief. Health institutions were often linked and located to churches and monasteries  
(Fig. 1) (20). With the introduction of anaesthetic methods from 1856 (21), X-rays 
from around 1900s (22) and antibiotics from the 1950s (23), medicine faced new 
opportunities and the focus was changed to treatment and therapy. As a result, major 
clinical advances characterized the 1950s. The goal was to cure everyone. Those who 
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could not be cured were often perceived as a defeat for the therapist. Care and relief 
lost much of their status (20). Parallel to the modernization that took place in 
medicine, a scepticism developed. The philosopher Ivan Illich went to a frontal attack 
against modern medicine, which he believed had done more harm than good. Illich 
claimed that death and suffering were removed from modern medicine (24).  
 
Cicely Saunders (1918-2005) is considered the founder of the modern palliative care 
movement. Her interest in palliative care and pain control developed early. She saw 
that particularly better pain control was  needed (18). To gain acceptance for her 
ideas, she graduated as a physician and started planning an inpatient unit for dying 
patients. St Christopher’s Hospice, London, was opened in 1967 and was the first 
modern research and teaching medical unit linking expert pain and symptom control, 
compassionate care, teaching and clinical research, pioneering the field of palliative 
medicine (25).  
The history of hospice philosophy and palliative care is complex and embraces 
humanistic ideas, medicine, public involvement and academic subjects. The 
entrepreneurs of the hospice movement often had a Christian conviction. Recent, 
Fig. 1. Healthcare at a French Hospice in the 18th century, Hospice des Dames du Calvaire, 
Marseille. Photo: Archives départementales. (Reprinted with permission.) 
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non-denominational approaches have promoted other systems and 
professionalization. However, many institutions today are still based on earlier work 
by Christian organizations, including continuation of deacon departments at hospitals 
and homecare for patients dying at home. The development of the field of palliative 
care has been a process evolving from voluntary work to a specific field of medicine 
(20). From 1975, the term "palliative care" was applied internationally. In many 
countries, including Norway, physicians  were not very visible in the palliative care 
field  until the end of the 1980s and the beginning of the 1990s (12). There was a 
debate whether care for the dying was a task for the health services. In 1988, the 
European Association for Palliative Care was established (18). In the same era, a 
collaboration was established between different professionals in Norway, with nurses, 
physicians, priests and social workers. The degree of interprofessional collaboration  
needed to care for seriously ill and dying patients is higher than in most other fields 
within the health services (12).  
 
History of palliative care in Norway 
Priority has been given to palliative care in three public health recommendations, 
from 1984 (26), 1987 (27) and 1997 (28), respectively. 
The first palliative care unit in Norway was opened at the university hospital in 
Trondheim in 1993 (29). Norway’s first palliative department in a nursing home was 
opened at Bergen Red Cross Nursing Home in the year 2000 (30). In 2011, palliative 
medicine was established as a separate discipline (formal competence field) on a trial 
basis in Norway (31).  
The Dental Health Act (“Lov om Tannhelsetjenester”) from 1984 (32) ensures that 
dental services are available to the entire population. It also specifically provides 
outreaching and regular treatment for some prioritized groups, including patients in 
need of oral palliative care. 
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1.4 Standardized care approaches and assessment tools in 
palliative care 
1.4.1 Standardized care approaches for end of life 
Since the mid-1980s, standardized care pathways have been an important tool in 
clinical improvement work (33). The purpose of standardized processes is to create 
security and predictability, ensure high professional quality and contribute to good 
cooperation, efficient resource utilization and measurable results (34). Internationally, 
there are a number of care plans for the final phase of life. The most widely known 
and used is the Liverpool Care Pathway for Care of the dying Patient (LCP) (35). The 
plan was developed by the Royal Liverpool University Hospital and Marie Curie 
Hospice in Liverpool for their own use, but eventually spread both nationally and 
internationally. The plan is intended for the short period from the patient is defined as 
dying until the first few hours after death. In 2009, LCP received negative news 
attention, claiming that the plan was used uncritically and could accelerate patients' 
death (36). The criticism led the British government to appoint an independent 
commission, which delivered its report in July 2013, the Neuberger review (37). The 
review report concluded that LCP was based on sound ethical principles and 
contributed to a good and peaceful death when the plan was used according to the 
intention. However, the report also concluded that poor implementation of the LCP 
had led to unfortunate situations for dying patients in hospitals, and the report 
recommended that the LCP should be phased out within a year (37, 38). The phasing 
out met with a lot of criticism and disagreement and was seen by many as a pure 
political decision (33, 38). In Norway, a continued but revised plan has taken over for 
LCP (39). The revised plan has been criticized for not being suitable for people with 
dementia and for many nursing home residents in general, and the critics believe the 
plan should rather have been replaced with competence-raising measures (30, 40, 41). 
Supporters of the plan believe it is a suitable tool and that it has led to greater 
awareness and expertise in palliative care (33, 40, 42, 43). 
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1.4.2 Assessment of subjective symptoms in palliative care 
Palliative care is intended to relieve troublesome subjective symptoms. Studies have 
shown that systematic assessment of symptoms is an important prerequisite for 
optimal relief (44). To that end, the Edmonton Symptom Assessment System (ESAS) 
was designed to perform repeated measurements of symptom intensity with minimal 
inconvenience to the patient (45). It is now one of the most used forms for self-
reporting of symptoms within palliative medicine (46). The original version of the 
ESAS form covers seven of the most common symptoms of long-term cancer: pain, 
fatigue, nausea, depression, anxiety, loss of appetite and heavy breathing. In addition, 
general well-being is assessed and the form has one open category where the patient 
can enter a specific symptom (45). The symptom intensity is indicated on an 11-point 
numeric scale. When the form was translated and used in Norway at the university 
hospital in Trondheim (St. Olavs hospital) in 1999, the open category was left out 
while xerostomia and motion pain were included in the form. This version, known as 
Trondheim Palliative Assessment Tool (T-PAT), was widely used in Norway and was 
recommended and included in the national palliative action program (47). ESAS has 
later been revised, and the revised version ESAS-r is now internationally used and 
recommended as standard palliative care assessment tool in Norway (48, 49). This 
revised version does not include dry mouth, but has an open category where this may 
be added.   
In medicine, performance status is an attempt to quantify the patient’s function and 
activities of daily life. The WHO (ECOG) Performance Status and the Karnofsky 
Performance Status (KPS) Scale are two widely used methods to assess the functional 
status of a patient. Both scales have been in the public domain for many years as 
ways to classify a patient according to their functional impairment, compare the 
effectiveness of therapies, and assess the prognosis of a patient. The Karnofsky 
Performance Status Scale (0-100) is one of the most commonly used. Low KPS status 
is one of the best prognostic indices, especially in cancer, indicating limited 
remaining life time (50, 51). WHO status is coarser and easier to use on a daily basis. 
WHO status is for example used in the selection of patients for certain types of 
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treatment. It is also a part of the ESAS form. There are comparisons of the WHO and 
the Karnofsky performance status scales (Fig. 2) (52). Since the scales have different 
wording, there is no completely linear relationship between them. 
  





Normal, no complaints 100 0 Fully active, able to carry on all pre-disease 
performance without restriction 
Able to carry on normal 
activities. Minor signs or 
symptoms of disease 
90 1 Restricted in physically strenuous activity but 
ambulatory and able to carry out work of a light or 
sedentary nature, e.g., light house work, office 
work 
Normal activity with effort 80 1 Restricted in physically strenuous activity but 
ambulatory and able to carry out work of a light or 
sedentary nature, e.g., light house work, office 
work 
Care for self. Unable to carry on 
normal activity or to do active 
work 
70 2 Ambulatory and capable of all selfcare but unable 
to carry out any work activities. Up and about more 
than 50% of waking hours 
Requires occasional 
assistance, but able to care for 
most of his needs 
60 2 Ambulatory and capable of all selfcare but unable 
to carry out any work activities. Up and about more 
than 50% of waking hours 
Requires considerable 
assistance and frequent 
medical care 
50 3 Capable of only limited selfcare, confined to bed or 
chair more than 50% of waking hours 
Disabled. Requires special care 
and assistance 
40 3 Capable of only limited selfcare, confined to bed or 
chair more than 50% of waking hours 
Severely disabled. 
Hospitalisation indicated though 
death not imminent 
30 4 Completely disabled. Cannot carry on any selfcare. 
Totally confined to bed or chair 
Very sick. Hospitalisation 
necessary. Active supportive 
treatment necessary 
20 4 Completely disabled. Cannot carry on any selfcare. 
Totally confined to bed or chair 
Moribund 10 4 Completely disabled. Cannot carry on any selfcare. 
Totally confined to bed or chair 
Dead 0 5 Dead 
Fig. 2.  Relationship between Karnofsky and WHO status. 
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1.5 Dry mouth in palliative care patients 
Saliva protects teeth and oral mucosa; it facilitates articulation of speech, is important 
for mastication and deglutition and is of significance for both oral homeostasis and 
for maintaining oral health (53-55).  
The saliva secretion is exclusively under the control of autonomous reflexes. Saliva is 
mainly produced by the parotid, submandibular and sublingual glands. Within the 
glands, the acinar cells are responsible for the volume of saliva secreted, and the duct 
cells are responsible for the composition of saliva (56). Unlike the autonomic nervous 
system in other places of the body, sympathetic and parasympathetic response in the 
salivary glands are not mutually contradictory (57). Increased activity in the 
sympathetic fibres of the glands leads to a slight increase in the rate of excretion and 
a more viscous quality of saliva. Increased parasympathetic activity, on the other 
hand, gives a large increase in thin-flowing secretion. Volume and consistency of 
saliva are thus dependent on the balance between the activity of the sympathetic and 
the parasympathetic nerve fibres (56, 58).  
 
1.5.1 Definitions of ‘dry mouth’ 
Dry mouth is a generic term that can include different conditions: 
Xerostomia is defined as the subjective sensation of dry mouth (59).  
Hyposalivation is defined as objectively and measured reduced salivation (59). 
Unstimulated flow rate of <0.1 ml/min is considered evidence of hyposalivation, 
defined as the objective finding of a reduced salivary flow rate (60). 
Salivary Gland Dysfunction (SGD) is defined as any alterations in the qualitative or 
quantitative output of saliva caused by an increase (hyperfunction) or decrease 
(hypofunction) in salivary output (61, 62).  
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1.5.2 Causes of xerostomia in palliative care patients 
Xerostomia occurs when the salivary flow rate is less than the rate of fluid loss from 
the mouth by swallowing, evaporation and absorption of water through the oral 
mucosa. Saliva in the residual volume is present as a thin film which varies in 
thickness with site. The hard palate has the thinnest film and when it is < 10µm thick, 
evaporation may rapidly decrease it to zero. This is generally associated with reduced 
secretion from the soft palate’s minor glands. Thus, xerostomia appears to be due, not 
only to a complete absence of oral fluid, but to localized areas of mucosal dryness, 
notably in the palate (63).  
Diseases causing oral dryness 
Several diseases are associated with salivary gland hypofunction (55, 64). In 
autoimmune diseases, such as Sjögren's syndrome, Rheumatoid Arthritis and 
Systemic Lupus Erythematosus, salivary gland dysfunction is largely related to 
structural changes in the salivary glands (65-68). In endocrine and metabolic 
disorders, like diabetes mellitus and thyroiditis, the oral problems are mainly related 
to pathophysiological changes that affect the formation of saliva (69, 70). In addition, 
there are a range of diseases that affect the autonomic outflow pathway involving the 
salivary gland innervation, the central nervous system and the salivation centre (71-
73).  
Side effects of head and neck irradiation treatment for cancer 
Most patients requiring specialist palliative care are cancer patients (74, 75). 
Xerostomia is extremely common in patients who have received radiotherapy to the 
head and neck region, with a prevalence of up 78-82% in advanced oncology groups 
(76, 77). In patients who receive chemotherapy, the prevalence of xerostomia has 
been estimated to be 50 % (76). 
Side effects of medication and polypharmacy 
The effect of medication on the saliva secretion is complex. Medications may 
simultaneously interact with the salivary reflex at different sites, on the central 
nervous system and/or on the neuroglandular junction on muscarinic, α- and 
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βadrenergic receptors and on certain peptidergic receptors (5, 78). Polypharmacy 
increases the risk of interactions and xerostomia (79, 80). It is uncertain to what 
extent medications induce xerostomia, most studies report the subjective complaint 
and there are only a few studies that measure objective changes in salivary 
flow (81).        
Opioid analgesics, sedatives, neuroleptics and anticholinergics are drugs that are 
often used in palliative care and continued into or added in the terminal phase (82, 
83). In a longer time-perspective, drugs for neuropathic pain are also often used, i.e. 
pregabalin, gabapentin and amitriptyline. These cannot be applied when the patient is 
no longer able to swallow tablets. Octreotide can be used with anticholinergics 
against ileus. Octreotide is given parenterally and can be given into the dying phase. 
Proton pump inhibitors are also used by some patients, especially those using 
corticosteroids and can cause dry mouth (79). The proton pump inhibitors are 
discontinued before the dying phase. 
Dehydration and xerostomia                     
Dehydration is a common cause of xerostomia among palliative patients. Common 
causes are insufficient intake of fluid, fever and medications, which affect the 
regulation of the salt and water balance in the body (84, 85). Mouth breathing has 
also been found to be a common cause of mucosal dehydration and a cause of 
xerostomia (86). Treating dehydration in palliative patients is challenging in view of 
complex physical, moral, ethical and cultural factors (87). 
 
1.5.3 Concequences of xerostomia in palliative patients 
Reduced Lubrication of oral surfaces 
The mucins in saliva are highly glycosylated proteins that form a hydrophilic network 
(88). This acellular film of mucin and water moistens and lubricates oral surfaces and 
gives saliva its texture and viscosity (89). The lubricating properties are important in 
the protection of mucous membranes, for mastication and deglutition and they 
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facilitate articulation of speech (53-55, 90). In seriously ill and palliative patients, the 
lack of lubrication by saliva may cause soreness, speech and deglutition problems.   
(3, 6, 61, 84, 91, 92). 
Decreased buffer capacity and protection of teeth 
The buffer properties of saliva consist of bicarbonate, phosphate and protein systems. 
These are important in the protection of teeth against acid attacks, but the buffer 
properties also have an important role in promotion and maintenance of a balanced 
oral microbiota (93, 94). Lipids in enamel pellicles are shown to protect the enamel 
surface against acid by retarding the lactic acid diffusion  (95, 96). Persistent and 
severe hyposalivation may lead to increased caries activity with lesions on cervical, 
incisal and cuspal tooth surfaces (97, 98).  
Lack of salivary clearance 
Containing substantial amounts of water, saliva has the ability to dilute and remove 
food substances, desquamated epithelial cells and microorganisms from the oral 
cavity (99-101). Saliva secretion and swallowing thus promote removal of bacteria 
and play an important role in balancing the microbiota (102, 103). In severely ill 
people, dry mouth will cause bacteria and food residues to accumulate in the mouth, 
causing a change the microbiological balance and thus discomfort and halitosis (2, 7, 
9, 91, 92, 104). 
Antimicrobial actions and healing properties 
The oral microbiota in healthy individuals is very diverse; more than 700 species 
have been identified in the oral cavity (105) and the oral cavity contains many niches 
for microbiological colonization (106). Saliva is important for both oral homeostasis 
and symbiosis (107), and is well known for its important role in maintaining oral 
health (108). Saliva provides antimicrobial activity through numerous proteins and 
peptides, including mucins, lactoferrin, lysozyme, lactoperoxidase, statherin, histatins 
and secretory immunoglobulin A, and promotes wound healing in several ways (55, 
107, 109). A reason why wounds grow faster in the oral cavity than on the skin is that 
saliva creates a humid environment that increases survival and functioning of 
 30 
inflammatory cells that are crucial for wound healing (110). An in vitro study has 
shown that saliva initiates the formation of pro-inflammatory macrophages, which are 
important for renovation and defence functions (111). Lack of saliva will destroy the 
microbiological equilibrium and combined with soreness and cracks and impaired 
immune system, the condition of oral dryness will often cause infections (2, 6, 7, 9, 
91, 92, 112, 113). 
 
Impaired taste and digestion 
Through direct mechanisms such as molecular, enzymatic and dilution, saliva can 
modify release or aroma compounds. Aroma perception is an important factor for the 
acceptance of food and thus for appetite (114). Food intake induces both mechanical, 
olfactory and chemical stimuli via neural reflexes, resulting in an increased salivation 
Fig. 3 The problem with oral dryness became encompassing and drew attention away from what you 
really wanted to spend your last time on, said Inger Anne.  
Photo of Inger Anne Bolme, who died of cancer in 2012, and her son Ruben, taken by Espen Bakken, 
Adresseavisen. (Printed with permission from the family and Adresseavisen.) 
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(90). Saliva plays an important role in the digestive processes; taste, breakdown of 
foods, masticatory function, bolus formation and deglutition (115). Lack of appetite, 
and hence nutritional intake in palliative patients, becomes a vicious circle where 
symptoms worsen and dehydration increases (7, 91, 116). Lack of liquid and 
degradative enzymes often lead to constipation (117). 
1.5.4 Treatments 
Saliva substitutes 
Saliva substitutes are available in a variety of forms, including sprays, gels and 
lozenges (118, 119). They are often based on mucins, methylcellulose or modified 
cooking oils (10, 119). A Cochrane review from 2011 concluded that there is no 
strong evidence that any topical therapy is effective in relieving dry mouth (10).  
Lemon and glycerine has been used for about 70 years as oral moisturizer for patients 
who experience xerostomia (120). However, lemon juice increases salivation and it 
has been claimed this can lead to a reflex exhaustion of the salivary glands over time 
(121). In addition, it has been claimed in several studies that glycerol`s absorption of 
water actually causes drying the mouth rather than lubricating it (122-124).  
Saliva stimulants 
A number of different stimuli may increase salivary flow (53). These can be triggered 
using chewing gums, lozenges, and by adding ascorbic and citric acid (118). For 
palliative patients it may be a problem to dissolve lozenges due to a total lack of 
saliva. Also, chewing gum requires adequate chewing force, which may not be 
available. 
Pilocarpine is a muscarinic receptor agonist, which has been shown to be an effective 
treatment for xerostomia (119, 125). Its use, however, involves some undesirable side 
effects, such as sweating, headache, urinary frequency and vasodilation (126).  
Salivary stimulants are only of benefit for those with remaining functional salivary 
gland tissue and a mild xerostomia (53). 
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Artificial hydration 
Artificial hydration is defined as providing solutions thorough non-normal routes, 
such as intravenously, subcutaneously, dermally, rectally or as a component of enteral 
nutrition or parenteral nutrition. Studies show conflicting results in terms of 
advantages and disadvantages (127). The advantage of artificial hydration is, among 
other things, that it prevents the accumulation of drugs and reduces fatigue, dizziness 
and reduced awareness (128). Disadvantages of artificial hydration include painful 
edema and prolonging the death process (129). 
Other approaches 
Hyperbaric treatment has been showed to result in significant decrease in xerostomia 
in irradiated head and neck cancer patients (130, 131). An electro stimulating device 
has been tried out (132), yet the experience and evidence is insufficient. Acupuncture 
has been tried as a treatment against xerostomia, but so far, there is insufficient 
evidence regarding the effect (133). Recent research attempts have been made to 
solve problems with xerostomia with nanotechnology (134). So far, it has not yielded 
results that can be implemented in clinical use. 
1.6 Oral palliative care 
Guidelines for oral palliative care 
In the wake of the development of the field of palliative medicine, some countries 
have developed national guidelines for oral palliative care (135-140). The guidelines 
are based on available evidence, but mainly on health care personnel`s experience 
and tradition. The main steps of the recommendations are fairly similar: Oral care is 
initiated by oral assessment using a recognized grading system (141), followed by 
care of the oral cavity consisting of cleaning teeth, gums/mucosa and lubrication of 
lips and mucosa (139). Although the main features of the procedures have much in 
common, the recommendations vary between the countries, especially when it comes 
to the oral care products. While the Norwegian guideline recommends glycerol as 
moisturizer, the use of glycerol in oral care procedures is discouraged in several other 
countries and in scientific literature, due to its possibly desiccating effect (121, 138). 
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If this is correct, it will adversely affect thousands of dying patients, resulting in 
chronic and increasing oral dryness. 
Oral palliative care in Norway 
Institutionalized, seriously ill and dying patients are entitled to free examination and 
treatment by a public dental officer – either a dentist or a dental hygienist (32). 
Patients living at home are entitled to the same, provided that they receive home care. 
Patient’s and User’s rights Act (“Lov om pasient- og brukerrettigheter”) defines 
similar rights for patients in Norwegian health institutions (142). Daily care should be 
provided by nursing staff in the hospital or nursing home. Oral care is a legally 










2.1 Overall aim 
To study some oral procedures in Norwegian health care institutions and to evaluate a 
selected sample of oral care products related to xerostomia in palliative care patients. 
2.2 Spesific aims 
Without intervention: 
 Identify procedures for oral palliative care in Norwegian Health Institutions 
 Identify oral care products applied in oral palliative care in Norway 
 Explore knowledge about oral palliative care among Norwegian health care 
personnel 
With intervention: 
 Investigate the effect of glycerol in three different concentrations on cells and 
cell layers in an oral mucosa model 
 Investigate the subjective effect of three different oral moisturizers on 
xerostomia, discomfort/pain, speech problems, taste, application method and 
preference in palliative care patients 
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3. Material and methods 
The materials and methods used in these studies (Paper I, II and III) are extensively 
described in the respective papers. A brief summary of the materials and methods 
used follows: 
3.1 Material 
Study I: A selection of hospitals (n=19) and nursing homes (n=57) participated.  
 
Study II: A total of 96 samples of Reconstructed Normal Human Buccal Mucosa 
(RNHBM) matured from biopsies from eight donors were used (Fig. 4). 
 
Study III: Thirty palliative patients with xerostomia met the inclusion criteria and 
were willing to participate.   
 
 
Fig. 4. Schematic illustration of reconstruction procedure, from biopsy, via cultivation of 2D cell 
cultures, keratinocytes and fibroblasts to the 3D RNHBM samples. 
Photoes/Illustration: S. Kvalheim/D.E. Costea 
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3.2 Methods 
Study I: Epidemiological method  
 
The geographically representative and randomly selected participating hospitals and 
nursing homes were asked to complete a questionnaire that included three closed- and 
three open-ended questions about oral care for terminal patients. If procedures 
existed, the respondents were asked to enclose or describe them. The charge nurse or 
deputy was asked to complete the questionnaire. 
 
 
Study II: In vitro, cell culture experiment 
 
The 96 RNHBM samples were exposed to 17%, 42.5% or 85% glycerol, or to 
distilled H2O (control). After 24 hours, the samples were paraffin embedded. From 
each of these, 384 sections were made available for analysis by either 
immunohistochemistry (IHC) to measure proliferation, apoptosis and cell-integrity, or 
histomorphometry, to measure epithelial thickness (Fig. 5.).  
 
 
Fig. 5. Illustration of procedure for exposure and analysis. 
Illustration/photos: S. Kvalheim. 
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Study III: In vivo RCT study  
 
The patients were exposed to a 17% solution of glycerol, Aequasyal® and Salient®. 
Each of the three products was applied after morning routine care and breakfast for 
three days. Each intervention was initiated with an oral care procedure (Fig. 6). The 
patients were blinded to the type of product applied. The order in which the products 
was applied, was determined by block randomization prior to interventions. 
Measures of subjective xerostomia, discomfort/pain and speech-problems were 
recorded before intervention, right after and two hours after application of the 
product. In addition, evaluation of taste, application method and patient preference of 
the products used were recorded at the two latter points in time. After all procedures 





Fig. 6. Illustration of the initial care procedure and the following intervention procedures with the 
products Aequasyal®, 17% glycerol solution and Salient®.  
Illustration/Photo: S. Kvalheim, K. Reisegg 
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3.3 Statistical analyses 





Frequencies of the responses were counted. Hospitals and nursing homes were 
compared using Fisher`s exact test. The analyses were performed with SPSS 20 (IBM 
Corp, IBM Statistics for Windows, Version 20.0, Armonk, NY). A 5% significance 
level was chosen for all analysis. 
Study II 
For comparisons of the parameters across 17%, 42.5% or 85% concentrations of 
glycerol in the in vitro study, linear mixed effects models were applied. In these 
models, for each outcome, concentration was entered as a categorical fixed effect. 
Donor was included and controlled for in the model as a random effect accounting for 
the possible correlation between samples from the same donor. The main results, 
based on the mixed models, were presented as estimated marginal mean values and 
Statistical methods Paper I Paper II Paper III 
Descriptive statistics ● ● ● 
Fisher`s exact test ●   
Linear mixed effects model  ●  
Intraclass correlation (ICC)  ●  
Likelihood ratio test  ●  
Ordinal logistic regression   ● 
Odds ratios (ORs)   ● 
Chi test   ● 
Table 1. Statistical methods used in the analysis. 
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mean differences, with 95% CI. Analysis were performed using the statistical 
package STATA version 15 (Stata, College Station, TX, USA).  
Study III 
For the categorical variables, percentages and frequencies were reported. To analyse 
differences between three oral care products, ordinal logistic regression was applied, 
with robust variance estimates to adjust the p-values for possible correlation between 
the nine repeated observations for each individual. Changes from the baseline 
measures for each of the oral care products and differences between the products 
right after and two hours after application were reported as odds ratios (ORs). To test 
if the distribution of preferred product was uniform for the three products, a chi-
squared test was applied. The statistical analyses were performed using Stata (version 






4. Summary of Results 
4.1 Study I 
Response rate 
The response rate was 84 % for hospitals and 79 % for nursing homes. 
Procedures for oral palliative care  
Twenty-five per cent of the responding institutions had no procedures for oral 
palliative care. Twenty-one different procedures were identified. A great variety of 
products is used for lubrication; the most common one being different concentrations 
of glycerol – 98% of which were above 30%.  
Attitudes and knowledge of oral palliative care 
An overall of 39 % reported that they had insufficient knowledge of oral palliative 
care. More nursing homes (56%) than hospitals (25%) answered they did not 
recognize that oral problems were of particular significance for palliative care 
patients.  
 
4.2 Study II 
Biological effects of glycerol on oral mucosa 
Epithelial thickness, proliferation and apoptosis were significantly increased by 
exposure to 42.5 % and 85 % glycerol. No significant difference in apoptosis and 
proliferation was found between controls and RNHBM. Cadherins, which are cell 
adhesion molecules indicating tissue integrity, were not significantly affected by 
exposure to any of the concentrations of glycerol tested. Glycerol affected tissue 
homeostasis (cell proliferation and apoptotic cell death), but not tissue integrity of 




4.3 Study III 
Response rate 
The response rate was 100% (no missing data). 
 
Subjective effects of the three different oral moisturizers 
Directly after application, compared with baseline, all products had a significant 
effect on the outcome variables: xerostomia, pain/discomfort and speech problems. A 
17% concentration of glycerol provided the best relief.  
After two hours, the glycerol solution had no significant effect on the same variables, 
whereas the effects of Aequasyal® and Salient® were maintained.  
 
Taste and texture 
The taste of Aequasyal® was disliked by 77% of the responders. Regarding Salient®, 
87% found the taste neutral, whereas all respondents found the taste of the glycerol 
solution agreeable or neutral. 
The texture of Salient® was found to be disagreeable and sticky by 60%. 
 
Application method 
Most respondents found the use of a soaked gauze pad (glycerol solution) or a spray 
(Aequasyal®) preferable to dispensing by means of a spoon Salient®. 
 
Patient preference  






5.1 Methodological considerations 
5.1.1 Internal and external validity of the studies 
The validity of a study can be defined as the extent to which the inference drawn 
from the study is warranted when account is taken of the study methods, the 
representativeness of the study sample and the nature of the population from which it 
is drawn (143). If internal validity is acceptable, it is valid for the sample studied, 
whereas external validity refers to the degree to which the effect of the treatment can 
be generalized to other patients and other settings than the ones investigated in the 
experiment (144, 145). In the following sections some of the most important aspects 
of internal and external validity are discussed. 
Study I - The questionnaire study 
Questionnaire studies often have the advantage that they are not very resource-
intensive and can be given to relatively large samples. This questionnaire study was 
sent to 76 randomly selected institutions with a geographical distribution throughout 
all 19 counties of Norway, in order to assure that the results could be regarded as 
representative and generalizable for the whole country.  
A disadvantage of the questionnaire method is that misunderstandings may be 
difficult to resolve. Choosing and formulating questions is crucial to the internal 
validity. Ideally, several issues should express nuances of a specific construct (145). 
However, too comprehensive questionnaires will often achieve a lower response rate. 
Even though a more comprehensive questionnaire with more items might produce 
more nuanced responses, for the purposes of this thesis, the important point was to 
ascertain if procedures did exist and what they entailed. Thus, in the present 
questionnaire study, emphasis was placed on using few and specific questions: three 
closed-ended and three open-ended questions, keeping each issue concrete and with 
 43 
less risk of misunderstanding. None of the respondents in this study expressed a need 
for clarification.   
Another disadvantage of questionnaire surveys is that the response rate may be low, 
often less than 50%. A low response rate will reduce both internal and external 
validity because responders may differ from non-responders, which may increase the 
risk of bias. Studies have shown that use of reminders may improve the response rate 
(146). The present response rate was 80% (79% for nursing homes and 84% for 
hospitals). This is a higher number than usual for this type of studies, which 
strengthens the validity of the results.  
Study II - The in vitro study 
In order to study effects of moisturizers at the cellular level, without having to 
involve patients or laboratory animals, functionally relevant, experimental models are 
needed. The conventional cell culture models, in which cells grow two-dimensionally 
in monolayers, lack the interactions with other cells by which they would normally be 
surrounded in real life (147). The reconstructed normal human buccal mucosa model 
(RNHBM) has been developed by Dr. Costea, University of Bergen and was 
originally developed for oral cancer research (148, 149). Advantages of the RNHBM 
are that it allows epithelial-mesenchymal interactions and offers a great flexibility for 
study design as each of its constituents can be modified. RNHBM also involves less 
ethical concerns than testing directly on the mucosa of living individuals, it is 
reproducible and can be standardized. Limitations of the RNHBM are the restricted 
life span, the lack of vascular and immunocompetent components and the fact that it 
is technically and financially demanding.   
Because immunohistochemistry (IHC) is an extremely expensive and time-
consuming procedure, only three randomized RNHBM samples from each 
donor/concentration were used. The fact that not all samples were used for these IHC 
analyses led to some reduction of statistical strength. Nevertheless, statistically 
analysis resulted in statistically significant results.  
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Another advantage of the model system is the possibility of producing a large number 
of RNHBM samples from one donor, often more than 20. From the six accepted 
donors a total of 96 RNHBM samples were obtained. The samples were considered at 
two levels; as donor and as individual RNHBM samples. Variability of the outcome 
can therefore be thought of as either being within the RNHBM samples from the 
same donor or between RNHBM samples in general. For that reason, the donor was 
included and controlled for in the model as a random effect accounting for the 
possible correlation between samples from the same donor. Concentration was 
entered as a categorical fixed effect. 
Possible sources of bias were primarily technology-sensitive factors, such as the 
viability of the cells and the time slot during manufacture. During maturation, the size 
could vary somewhat, which obviously affected the exposure surface. Due to the 
concave centre part of the RNHBM sample and the potential for the outer parts not 
being exposed, all measurements were made in a standardized distance from the 
centre. 
 
Study III - The RCT  
The RCT is the most scientifically rigorous method of hypothesis testing available 
and is regarded as the gold standard trial for evaluating the effectiveness of 
interventions (150). Empirical evidence indicates that inaccurate or inadequate 
reporting of information is associated with biased estimates of treatment effect (151). 
CONSORT 2010 Guidelines have therefore been used as the basis for this RCT. 
On the basis of ethical, financial, practical and resource-intensive considerations in 
relation to the patient group (152), sample size is relatively small and only a few 
variables were explored. Still, the sample size was sufficient for adequate statistical 
analysis. In order to avoid having to include unnecessarily large numbers of 
participants, a crossover design was applied in this RCT. Each case was self-matched 
by serving as its own control (153). With the cross-over design performance bias, 
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systematic differences in the provided care, and detection bias, systematic differences 
between comparison groups, were avoided (154). 
The external validity of this study has some obvious limitations. Healthier individuals 
may perceive their oral dryness, speech problems and discomfort as less invasive than 
severely ill, palliative patients and may, to a greater extent, be able to prevent their 
problems themselves when needed. The results of this study are thus not necessarily 
generalizable for other types of xerostomia patients. 
A block randomisation, with blocks of six, was used to ensure a balance in the 
number of patients allocated to each of the sequences in the trial (150). Studies have 
shown that treatment effects have been exaggerated in trials in which allocation 
treatment have not been concealed (155). In this RCT, allocation concealment was 
completed by one of the co-authors who was not responsible for the recruitment.  
Blinding means that the nature of the treatment is not known by the parties involved 
in the RCT experiment. The object of blinding is to reduce the risk of bias, best 
accomplished with a double-blind study, i.e. that both patient and researcher are thus 
blinded. However, for a number of reasons a double-blind method cannot always be 
applied in clinical studies, and a single-blind method must then be applied. (144). In 
our context, the three oral moisturizers were presented in neutral containers without 
label. Both participants, data collectors and data evaluators were kept ignorant of the 
assigned treatment. The dentist who carried out the intervention could not be 
similarly blinded because of differences in application method, which sufficed to 
identify the treatment.  
A significant element of uncertainty was related to the fact that while only very ill 
patients were recruited, they would hopefully survive and remain in an unchanged 
health condition throughout the entire study period. That no participants withdrew 
from the study or were lost to follow-up, helped increase internal validity and avoid 
attrition bias, i.e. biased occurrence and handling of deviations from protocol and loss 
to follow up (156). The reasons for this was primarily due to knowledgeable and 
professional help with enrolling suitable patients, but also obviously a great deal of 
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luck. In such patients, the health condition can change quickly and radically from one 
day to the next (157).  
Another source of error was that it was not possible to standardize the interventions 
within the ethical and practical framework. Our study could not interfere with the 
procedures of oral care of the institution, although these were used only to a limited 
extent during the intervention period. However, in theory, the hospital`s and patient`s 
own oral care procedures may have affected the effect of the interventions. The study 
intervention was applied right after breakfast and morning routine care. For ethical- 
and health reasons, the patients could not be prevented from intake of food or drink at 
other times and in between the times of exposure. It can therefore not be precluded 
that nutrition intake may have affected the results. 
A challenge with clinical trials that test commercially available products is that they 
are often sponsored by the industry. The inherent suspicion that the results may not 
be completely independent is then difficult to rule out due to the potential economic 
profits of positive results (158). Our RCT has received no financial support other than 
funds from the University of Bergen.  
5.2 Ethical considerations 
In this thesis, two of the studies, the in vitro study and the RCT, required approval by 
the Regional Ethical Committee (REK). The in vitro study required approval for 
including participants as donors for the oral mucosa model, and for storing the cells 
according to the approval and the guidelines of the University of Bergen. The RCT 
obviously required REC approval for including vulnerable patients for the 
interventions. Ethical issues are central to palliative research. The Helsinki 
Declaration acts as a form of ethical constitution for human research (152, 159).  
Until palliative medicine was established as a speciality, knowledge within the field 
was built on tradition and experience (20). Allowing research on groups and 
individuals who are entitled to special protection is necessary because lack of relevant 
knowledge may lead to inappropriate treatment and put patients at risk. Research is 
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thus a necessity, also for demented, elderly, children, pregnant and dying. At the 
same time, strict limits have been set for research on minors and others who cannot 
themselves give consent. Such research can only be carried out when it is expected 
that the research will benefit these groups and if the research cannot be done on other 
groups (152). The RCT was approved because none of the products had any known 
side effects, palliative patients can deviate from other patients with similar oral 
dryness problems and because the participants could benefit from the interventions.  
5.3 Findings 
5.3.1 Procedures and knowledge of oral palliative care 
Daily tooth brushing is for most people essential for perceived well-being. Therefore, 
it is strange that such care is not equally obvious when taking care of others. Article I 
showed that 25% of the included institutions did not have procedures for oral 
palliative care. Presumably, some oral palliative care procedures were undertaken, 
despite the lack of formal ones. However, a more likely scenario was that the patients 
received no oral care although procedures existed. The latter alternative was indicated 
in several answers to the open-ended questions in the survey. Explanations were lack 
of time, insecurity regarding clinical procedures, the feeling of intruding on the 
patient’s privacy or refusal by the patient. The same kinds of responses have been 
reported in previous studies (160-164). A recent study states that even though oral 
care is recognized as an essential aspect of nursing, it is often not considered a 
priority, especially when various complex patient needs have to be managed (165). A 
Swedish study, which aimed at exploring and describing attitudes relating to 
xerostomia among health care professionals, found that the condition was considered 
to be an underestimated and ignored problem, although commonly occurring (166). 
Educational issues 
The above raises the question of whether the nursing educational programs are 
adequate concerning oral health. Several studies point to too few teaching hours and 
insufficient clinical practice in oral health procedures (160-163). Lack of oral-health-
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related content in the curricula of nursing education is mentioned as a reason for the 
refusal to give oral health related care. In a survey study among 235 nurses in the 
USA, 75% received less than 3 hours of oral health related education/training and 
60% reported having no requirements for clinical training in the assessment of oral 
conditions (164). In a Swedish study among 137 nurses, only four reported having 
received adequate training in oral care during their education (161). In the same 
sample, 45% objected to examining the oral cavity and stated patient integrity as the 
main reason. In contrast, the findings in a Norwegian study from 2009 appeared to 
contradict that the basic education in oral care of long-time-care (LTC) professionals 
was inadequate (167). There might therefore be other explanations for the poor oral 
hygiene in many institutions. 
Little prestige and low priority 
In our questionnaire study, almost half of the nursing homes did not recognise that 
oral problems were that important; probably because the personnel were not 
sufficiently aware of their significance. The results of this study do not indicate 
whether or not patients from such institutions actually received adequate oral 
hygiene, but no doubt oral problems did exist there. This also agrees with the results 
of numerous previous studies, (2, 6, 168, 169).  
A positive attitude and sufficient knowledge in healthcare professionals are 
prerequisites for adequate care of the oral cavity in serious illness. Nevertheless, 
studies indicate that it is difficult to encourage healthcare providers to be proactive 
with oral disease prevention and to promote good oral care (160, 162, 163). 
Researchers have found a disparity between recorded and true prevalence of 
xerostomia (170). The reason is unclear, but probably it reflects both healthcare 
professional-related factors (e.g. perception that the symptom is unimportant) and 
patient-related factors (e.g. perception that other symptoms are more important) (64, 
170, 171).  
Obviously, fields that are perceived as more challenging are more popular and 
prestigious (172). Geriatrics and psychiatry are among the lowest ranked specialities 
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(173). It can be assumed that similar rankings regarding daily work tasks exist in 
nursing and that these will influence priorities in care. Miller suggests that the trend 
toward inadequate oral care is caused by a reluctance to develop best practice 
guidelines and nursing protocols, relegating the responsibility for oral care to lower 
grades of nursing staff, which amplifies the negative effect (122). In a survey among 
physicians and medical students, low prestige scores were given to diseases and 
specialities associated with chronic conditions, with less visible treatment procedures 
and with elderly patients (172). It can be assumed that the perception of oral 
palliative procedures by health personnel is similarly assessed. 
Does the dental team have a role in palliative medicine? 
During the implementation of the RCT study, some nurses at Haraldsplass hospital 
expressed that the patients might be more interested in oral care if offered by a dentist 
or hygienist, than by a nurse. This was not investigated in our study, but raises an 
important question: Should oral care in institutions be carried out by dental 
professionals rather than by the nursing staff? Wiseman claims that the importance of 
dental care is often overlooked because the dentist is not included in the palliative 
care team (8). In a Japanese study it is claimed that more dental services should be 
made available (174).  
In the literature on palliative treatment, cooperation is often referred to, but the dental 
team is rarely mentioned in that context (175, 176). The fact that the category dry 
mouth, which was added to the Norwegian version of the ESAS form in 1999, was 
removed in the revised version from 2010, expresses a lack of focus on and 
understanding of oral issues, rather than oral problems not being of significant 
importance (47). The discipline palliative medicine is relatively new and is constantly 
evolving. Being aware of and positive to cooperation with other disciplines opens the 
possibility of focus on oral problems. However, it is a well-known challenge that oral 
health is not equated with general health (177-179) even though oral health is closely 
related to systemic health (180).  
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Expectations of patients and relatives 
In regard to the attitudes of the healthcare professional on the one hand and the 
expectations of the patients on the other: Patients participating in the RCT indicated 
that they did not want to bother the nursing staff unnecessarily. Lack of expectations 
about oral care may not only be in the nursing staff at the hospital, but also in patients 
and relatives.  
Differences between nursing homes and hospitals 
One reasons why far more hospitals than nursing homes stated that they considered 
oral problem of significance, could be that the type of patients and treatments differs 
significantly between hospitals and nursing homes. Previous studies indicate that oral 
care is more emphasized in intensive care units (181) than in palliative care units 
(169), presumably because it is necessary to protect patients from aspiration of 
pathogenic bacteria (182, 183). Hospital departments have more physicians and 
nurses, whereas assistant nurses with lower education dominate in nursing homes. 
Differences in occupational groups can also explain the differences in self-perceived 
knowledge about oral care between nursing homes and hospitals in our questionnaire 
study. 
 
5.3.2 Glycerol, indication or contraindication for use 
Recommendations regarding glycerol as an oral moisturizer in palliative care are 
remarkably contradictory. Some studies claim that glycerol used for this purpose, is 
directly unfavourable because of its desiccating effect (122, 136, 138, 184). The 
national guideline in Norway (139), recommends the use of glycerol as moisturizer in 
oral palliative care. Despite this being the subject of debate for over 80 years, the 
guideline is in fact solely based on expert clinical experience, not on good quality 
scientific evidence. Consequently, it may be questioned if it satisfies the requirements 
of Evidence-based medicine (EBM) or Evidence-based health care (EBHC), which 
are defined as “the conscientious, explicit, judicious and reasonable use of modern, 
best evidence in making decisions about the care of individual patients” (185). 
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However, in the absence of good scientific evidence, experience based knowledge, 
such as the Norwegian national guideline, must be used (186). 
Biological effect 
The conflicting recommendations about the use of glycerol as a moisturizer and 
knowledge that concentrated glycerol appeared to be dehydrating (187) was a starting 
point for the desire to study its biological effects in the in vitro study (Study II). 
Epithelial tissues maintain their homeostasis by balancing the continuous cell loss 
from desquamation on the surface with proliferation of cells in the basal cell layer 
(147, 188). Thus, increased proliferation is actually a natural response of a healthy 
epithelium, as response of increased cell loss(188).  
Of concern in this study, however, is the fact that the increase in cell proliferation 
was overbalancing apoptosis in the two highest concentrations (42.5% and 85%), as 
indicated by the increase in epithelial thickness. For long-term exposure, one might 
fear that the use of high concentrations of glycerol would increase the risk of 
malignant transformation and increase the risk of accumulation of DNA errors with 
each cellular replication. However, the use of glycerol must be seen in a clinical 
context and in the time frame of palliative patients. The study shows that glycerol 
does not affect tissue differentiation or tissue integrity, indirectly suggesting a 
maintained barrier function. Glycerol's desiccating effect was not investigated in this 
study. 
Clinical short-term effect 
In our RCT (Study III), glycerol produced significant reduction in xerostomia just 
after application, but was no longer efficient after 2 hours. An American study from 
1997 indicates the opposite tendency; that patients with xerostomia became drier the 
first few days after lubrication, regardless of the humectant received, but experienced 
improvement from their dry mouth after four days (189).  A limitation with our study 
was that the follow-up time after intervention was only 2 hours and the fact that the 
products were only applied once, thus precluding the possibility of investigating the 
long-term effect. Nevertheless, in this patient group, the immediate effect is more 
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important. A weakness with several studies referring to the use of glycerol is that the 
concentration of glycerol is not reported (123, 189), despite the fact that the 
concentration is crucial in regard to its hygroscopic effect (190). In this study, we 
offer scientific evidence that while glycerol gives immediate relief and probably is 
not harmful to the tissue by short-term use and at low concentrations; its moisturizing 
effect disappears quickly. 
 
Fig. 7. An old illustration of the use of glycerol against dry 
mouth reflects an 80-year-old problem that still remains 
unresolved. Showing a group of college students testing 
different combinations of lemon juice and glycerol for oral 
care in 1969.  
Source: The American Journal of Nursing (1969) 
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5.3.3 Clinical findings in the RCT 
Palliative care patients may experience that several bothersome symptoms and 
conditions may occur because of oral dryness and several studies highlight clinical 
findings and symptom management in palliative care (3, 91, 165, 169, 191). Several 
studies address oral symptoms resulting from cancer or radiotherapy, such as pain, 
soreness, swallowing problems, speech impairment, oral infections, increased 
incidence of caries and others (3, 122, 165, 169, 192). The symptoms are consistent 
with the patient group in this RCT. Most patients in the study used opioid analgesics, 
sedatives, neuroleptics and anticholinergic drugs; some also used neuropathic pain 
medication, octreotide against bowel obstruction and proton pump inhibitors against 
reflux ailments. Many intervention studies have been conducted with regards to the 
management of dry mouth (10, 193) on a wide range of different patients with diverse 
complaints caused by autoimmune conditions, hormonal disorders, immune 
disorders, patients undergoing haemodialysis, medication-induced xerostomia, and 
radiotherapy (10, 193). In the Cochrane rapport from 2011 on topical therapy 
interventions for the management of dry mouth, randomized crossover trials were 
considered to be an appropriate design for research in this area. Dry mouth symptoms 
are likely to be stable over time and topical therapies are likely to offer relatively 
short-lived effects, which are likely to be reversible (10).  A randomized crossover 
design was applied in this RCT. 
Palliative patients as participants 
The reason why palliative patients were chosen for our RCT was twofold: It was 
assumed that their need for oral care might be greater and/or different from less 
compromised patients, and that in such patients, possible differences between 
products might be more discernible. To our knowledge, very few clinical trials have 
compared the effect of saliva substitutes in palliative patients. Only one clinical trial 
on palliative patients was found (194). Sweeney et al. tested two oral sprays, a mucin-
containing spray versus placebo, in 35 hospice patients. Unlike our RCT, Sweeney 
had a follow-up period of 14 days, where the patients used the allocated oral spray as 
much as possible every day, and 26 patients remained in the study on day 14. There 
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was no statistically significant difference between those on active and placebo when 
oral symptoms were recorded. The investigators still concluded that both sprays 
provided some degree of symptomatic relief of oral dryness for many of the 
participants, as they wanted to keep the spray after the intervention period.  
What possible alternatives could there be? 
In our RCT we found effect after two hours for two of the products. Since a majority 
of patients tolerated these products poorly, it may be natural to think of alternatives. 
An obvious alternative is the possibility of modifying the two products that had 
effect; if possible to dilute Salient® to make it less sticky or add another flavour to 
Aequasyal®. Glycerol gave good relief immediately, but quickly lost its effect. One 
can question whether there is in fact any significant difference between such a low 
concentration as 17% glycerol and pure water. 
A major problem, which will not be solved regardless by application of topical saliva 
substitutes in the mouth, is the dryness that extends down the throat. This was often 
the largest problem for the most severely affected and ill patients. Pilocarpine, which 
is a parasympathomimetic drug, is, to our knowledge, rarely used in Norwegian 
hospitals and nursing homes. In some studies, unpleasant dose-dependent side effects 
have been shown, while several studies show that pilocarpine is more effective than 
placebo (195). In patients with functioning salivary tissue, Pilocarpine may offer an 
opportunity that will also help to moisturize the pharynx. But experience and 
evidence for the application in palliative patients is sparse. 
Intravenous (IV) fluid supply is used and there has recently been a slight shift from 
the perception that terminating IV fluid completely in the terminal phase is correct, to 
instead making individual adjustments according to patients’ and relatives’ wishes, 
since there is contradictory evidence and experience (196-198). 
Oral care is valued  
As there is no optimal oral moisturizer available, it is nevertheless important that oral 
care is carried out. Of the patients in the RCT, almost all expressed that having teeth 
and gums cleaned, provided relief and some commented that the cleaning was even 
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the best part of the intervention procedure. A majority of the patients in the RCT were 




Fig. 8. One of the patients in the RCT study 
had syringomyelia as an additional diagnosis. 
The disease had led to stiffness in the arms 
and fingers so that she could not open a 
toothpaste tube. She had not been able to 
brush her teeth for several weeks. 
Photo: S. Kvalheim (with permission from the 
patient) 
Fig. 9. This man from the RCT study wanted 
help because he felt he had an "outgrowth" in 
his throat. The discomfort was due to large 
amounts of fungi. 




6.1 Overall conclusion 
Oral palliative care has only to a small degree been studied. Research within this field 
must be considered pioneering work. For that reason, this thesis was initiated with the 
survey study that indicated how this treatment was implemented in practice by the 
relevant institutions, and what attitudes existed among care givers towards such 
treatment. The widely differing products used suggested a lack of solid scientific 
basis and uncertainty regarding their use. An experimental, biological laboratory 
study was therefore initiated to explore the biologic consequences on a cellular level 
of the use of different concentrations of glycerol, the most commonly used product in 
Norwegian health institutions. Finally, an RCT-study was performed in order to 
investigate how the most recommended products were received by those most needy 
of oral care:  palliative patients. The hope and aspiration have been that this thesis 
might make some contribution towards widening the body of knowledge within the 
field of oral palliative care. 
6.2 Specific conclusions  
Xerostomia is a major problem among palliative care patients. Nevertheless, many 
nursing homes and hospitals lack proper procedures for oral palliative care. There are 
obvious challenges related to lack of knowledge and attitudes in relation to such care. 
Glycerol, tested on an oral mucosa model, does not seem to harm the mucosa on a 
cell-level, provided it is applied in a low concentration and used for a limited period 
of time. Higher concentrations (42,5 % and above) may result in increased 
proliferation and cell-apoptosis, which can theoretically be associated with malignant 
transformation of the epithelium. 
Among the agents tested in this RCT study, glycerol was the preferred product 
despite the fact that it was the least efficient 2 hours after application, at which time it 
had lost its effect. Both of the other two products, Aequasyal® and Salient®, gave 
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statistically significant improvement in xerostomia, but were not well tolerated by 
this group of patients due to their taste or consistency.  





7. Future Perspectives 
Scientific approach 
Several aspects of dry mouth in palliative care patients need to be further 
investigated: 
 Mucosal and salivary properties in seriously ill patients with xerostomia need 
to be investigated, in order to develop well adapted products for appropriate 
oral care  
 Other kind of products 
 Other approaches for hydration 
 
Clinical and educational approach 
Oral health problems in severely ill patients should be made known to healthcare 
professionals in hospitals and nursing homes. Emphasis must be placed on 
information about the relationship between oral and general health, as well as on 
future models for health care education and organization of oral care in institutions. 
 
Patient-centered approach 
It seems self-evident that oral health should be implemented consistent with other 
kinds of health care.  
 Oral care must be recognised as a necessary daily care and the nursing staff 
must be responsible for ensuring that oral care procedures are carried out. 
 It must be assured that lack of awareness of oral palliative care in healthcare 
professionals does not prevent patients from accessing symptomatic treatment. 
 Patients should be given the opportunity of trying different lubrication 
products or alternative ways of hydration. 
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End-of-life palliative oral care in Norwegian health institutions. An exploratory study
Objective: To explore circumstances surrounding procedures and knowledge regarding oral care for ter-
minal patients in Norwegian healthcare institutions.
Methods: A questionnaire was distributed to randomly selected hospitals (n = 19) and nursing homes
(n = 57) in central and rural parts of Norway. The questionnaire included three closed-ended and three
open-ended questions about oral care for terminal patients. If procedures existed, the respondents were
asked to enclose or describe them.
Results: The response rate was 84% for hospitals and 79% for nursing homes. Of the responding insti-
tutions, 25% had no oral care procedures, nor did 48% recognise their importance. Insufficient knowl-
edge about oral care was reported by 39%. Twenty-one different procedures were identified, and a great
number of oral care products used. The most common was glycerol, used by 36% of the institutions.
Only 2% used a concentration below 30% – the limit above which the glycerol has a desiccating rather
than a moistening effect. The most common patient complaint was dry mouth (49%), followed by pla-
que, food particles and fungus infections, each experienced by 19%. The most common problem for the
personnel was lack of knowledge (43%) and patient cooperation (38%).
Conclusions: Some terminal patients do not receive adequate palliative oral care in Norwegian health-
care institutions. Those that do are exposed to a great number of undocumented procedures and some-
times harmful products. There is a need for evidence-based procedures for oral care for terminally ill
patients in health institutions, establishing interprofessional palliative healthcare teams and in particular
improved training of the nursing staff.
Keywords: palliative care, oral health, oral hygiene.
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Introduction
Ideally, dying should be painless, peaceful and
dignified. Palliative care for dying patients is
defined as comprehensive, interdisciplinary care
of patients and families facing a terminal illness,
focusing primarily on comfort and support1. The
more specific concept of palliative oral care has
been defined as the management of patients with
far-advanced disease where the oral cavity has
been compromised, either directly by the disease
or indirectly as a consequence of its treatment1.
The term ‘general palliative care’ is often associ-
ated with cancer treatment, but WHO suggests
that expertise from this field should be extended
to treatment of other groups of severely ill per-
sons such as elderly nursing home residents2.
The majority of terminally ill patients have a
wide range of oral symptoms, including speech
difficulties. The oral cavity is frequently dry;
the tongue adheres to the mucosa and impedes
the expression of remarks, gratitude or desires.
Increased salivary viscosity may inhibit swallow-
ing and taste3,4. Thirst is a common problem for
severely ill patients. Dehydration may be due to
reduced liquid intake, diarrhoea, fever or vomit-
ing. Dry lips can lead to cracking, particularly
when smiling, and oral infections and pain occur
easily when the lubricating, protective and anti-
microbial effect of saliva is lost5,6. An important
© 2015 John Wiley & Sons A/S and The Gerodontology Association. Published by John Wiley & Sons Ltd 1
aspect of palliative care is to prevent halitosis,
which can be off-putting for relatives and friends
who wish to bid farewell. This is a time when dig-
nity and self-respect are essential7.
Norwegian data indicate that 56% of terminal
patients complained about dry mouth8. In addi-
tion, 49% complained about thirst and 74%
about altered eating habits, which may to some
extent be related to xerostomia.
Such problems are probably mainly caused by
the medications used in palliative medicine (for
instance opiates, glucocorticoids and antidepres-
sants) in combination with mouth breathing and
dehydration. Infusions may to some extent allevi-
ate the dryness of the mouth and thirst. However,
these are only used when likely to improve the
patient’s quality of life; otherwise, oral care with
frequent moistening of the oral mucosa should be
implemented9,10.
The object of all kinds of palliative care is to
provide patients with relief from the symptoms,
pain and stress of a serious illness – whatever the
diagnosis and to improve quality of life for both
patient and family.
To this end, WHO published in 2004 palliative
care guidelines11. However, their recommenda-
tions on oral care are fairly general, and no evi-
dence for their efficacy is provided. They do not
specify guidelines to alleviate specific symptoms
related to dry mouths and lips, nor the optimal
frequency of such treatment.
Searching in the literature for evidence-based
procedures reveals that little research has been
published within this field. Still, many different
procedures for oral care for critically ill patients
exist12–15. However, with a few exceptions like
the documented effect of usage of electric tooth-
brushes and fluorides on oral health, they are
based on expert opinion15. Sometimes recommen-
dations rely on research made on healthier target
populations16. Some authors claim that oral care
is performed every 2–4 h or on a daily basis17;
others report that such procedures are not always
carried out in hospitals and nursing institutions
caring for these patients13.
Palliative oral care is shown to be effective in
alleviating the oral symptoms of terminally ill
patients18. However, for a number of reasons, oral
care is not always adequate19. The time and
resources allocated to this task may be insuffi-
cient, and the staff were inadequately trained and
therefore lack the necessary skills. Another impor-
tant reason is that the recommendations in many
respects are not evidence based. Undocumented
use of glycerol and undefined frequency of oral
care are examples of this. In fact, it has been
claimed that products commonly used may be
contraindicated for routine oral hygiene, such as
hydrogen peroxide, sodium bicarbonate and
lemon and glycerol20,21.
Like in the above-mentioned studies, no formal,
generally accepted and evidence-based Norwegian
procedures on oral care for end-of-life patients
exist; local and differing ones have been devel-
oped and applied with little or no evidence base.
No legislation compels all health institutions with
terminal patients to implement systematic pallia-
tive care, although such plans are being discussed.
However, all patients in Norwegian health institu-
tions have a legislated right to ‘adequate and indi-
vidually adapted treatment’ (including oral care).
What this means in practice is presently up to the
caregivers to decide, if possible in cooperation
with the patient. Some regional hospital and hos-
pices have palliative units – most do not.
To provide end-of-life patients with adequate
evidence-based oral care, an important first step is
to explore the current situation with a fairly open
overview. With this in mind, the purpose of the
present investigation was thus (i) to record to
what extent Norwegian institutions have proce-
dures for oral care for terminal patients, (ii) to
study the content of these, (iii) to record the level
of knowledge of the nursing staff regarding pallia-
tive oral care and (iv) to identify possible prob-
lems associated with oral care. The intention of
this exploratory study is to reveal areas that may
later be the subject of targeted experimental
research in an effort to establish evidence-based
procedures.
Methodology
A questionnaire regarding palliative oral care for
end-of-life patients was developed by the authors
all of whom have extended experience within this
field. The items were the result of a consensus
within the group. A pilot study was conducted
prior to this investigation among a small group of
nurses to ascertain that the wording was compre-
hensive and easily understood. The wording was
adjusted according to received responses. The
questionnaire was sent by mail to 76 Norwegian
health institutions. In the letter, complete contact
information was given, including main line tele-
phone number, cell phone number and e-mail
address. Self-addressed and stamped envelopes
were provided. The health institutions were ran-
domly chosen by drawing lots, and one hospital
and three nursing homes for each of the country’s
© 2015 John Wiley & Sons A/S and The Gerodontology Association. Published by John Wiley & Sons Ltd
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19 counties were thus selected. The charge nurse
or the deputy was asked to complete the ques-
tionnaire.
An accompanying letter explained that the
study concerned oral treatment of patients who
matched the Liverpool Care Pathway (LCP) crite-
ria22: the patient should have been considered, by
an interdisciplinary team, to be dying. The life
expectancy is then usually a matter of days or
even hours. This often implies that the person is
bedridden, incommunicative for extended periods,
can drink only small quantities of liquid and can-
not swallow tablets. After 6 weeks, a reminder
letter was sent to all institutions.
The questionnaire contained three items with
predetermined response categories (wording and
response categories shown in Table 1). It addition-
ally contained three open-ended items, which
were designed to explore further the circum-
stances surrounding palliative oral care. The
open-ended approach was chosen to explore,
without the limitation of predetermined catego-
ries, the thinking behind the procedures. In the
first one of these, the respondents were asked to
describe or document what procedures for pallia-
tive oral care for end-of -life patients existed; in
the second one, to report who had formulated the
procedures; and in the third, to explain what
characterised oral problems for the terminally ill
patients and for the personnel treating them. The
responses to the open-ended items were later
interpreted and categorised by the first author,
who, when in doubt, conferred with the other
authors.
During this categorisation, procedures with
approximately similar methodologies and use of
oral care products were identified. An effort was
made to assess each procedure as objectively as pos-
sible. Within each identified procedure, the meth-
ods and/or oral care products used were similar, if
not necessarily completely identical. Who authored
the procedures and what characterised oral prob-
lems for the terminally ill patients and for the per-
sonnel treating them were similarly recorded.
Statistical methods
The frequencies of the responses were counted.
Groups were cross-tabulated in 2 9 2 tables and
compared using Fisher’s exact test. In comparisons
between the groups, the variables were dichoto-
mised as follows: regarding all the variables in
Table 1, the responses ‘Do not know’ were excluded
from the analyses. Regarding mouth cleaning pro-
cedures shown in Table 2, the responses ‘Teeth
only’, ‘Mucosa only’ and ‘Teeth and mucosa’ were
combined into one category (defined as ‘Cleaning
procedures’), vs. ‘Do not clean’. Similarly, the
responses ‘Glycerol ≤30%’, ’Glycerol >30%’, ‘Glyc-
erol, unspecified concentration’ and ‘Other than
glycerol’ were combined (defined as ‘Use lubrica-
tor’) vs. a ‘No lubrication’.
The analyses were performed by means of SPSS
20 (IBM Corp, IBM Statistics for Windows, Ver-
sion 20.0, Armonk, NY). A 5% significance level
was chosen for all analyses.
Results
Response rate
The response rate was 16 of the 19 hospitals
(84%) and 45 of the 57 nursing homes (79%).
The overall response rate was 80%. There are 46
hospitals and 1050 nursing homes in Norway.
The responding institutions thus represented 16/
46 (35%) of all hospitals and 45/1050 (4%) of all
nursing homes in the country. No responders had
questions relating to the questionnaire.
Items with predetermined categories
The frequencies of the items with predetermined
categories, overall and split into hospitals and
Table 1 Items with predetermined categories. Distribu-
tion of responses and comparisons between health insti-








Do you have procedures for oral care for the dying
patient?
Yes 13 (81) 33 (73) 46 (75) 0.74a
No 3 (19) 11 (24) 14 (23)
Do not
know
0 (0) 1 (2) 1 (2)
Do you feel that you have sufficient knowledge of this
type of oral care?
Yes 11 (69) 26 (58) 37 (61) 1.00a
No 5 (31) 14 (31) 19 (31)
Do not
know
0 (0) 5 (11) 5 (8)
Do you recognise that oral problems are of important
significance?
Yes 12 (75) 20 (44) 32 (52) 0.07a
No 3 (19) 20 (44) 23 (38)
Do not
know
1 (6) 5 (11) 6 (10)
aIn the comparisons, ‘Do not know’ and ‘No informa-
tion’ are not included.
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nursing homes, are shown in Table 1. Of the 61
participating institutions, 15 (25%) had no proce-
dures, 24 (39%) reported insufficient knowledge
of this type of oral care, and 32 (52%) still recog-
nised that oral problems were of important signifi-
cance.
Open-ended items
Procedures and implementation. Eleven of the 13
hospitals (85%) and 18 of the 33 nursing homes
(55%) that did have procedures for palliative oral
care for end-of-life patients returned printed cop-
ies of these. In addition, one of the 13 hospitals
(8%) and 14 of the 33 nursing homes (42%) sub-
mitted exhaustive descriptions of the procedures.
One hospital and one nursing home (8% and 3%,
respectively) claimed to have procedures, but did
not document them.
Categorisation of the responses revealed 21 dif-
ferent identifiable procedures. These differed
widely, both in terms of what actions were imple-
mented and oral care products used. Within the
21 procedures, five actions were identified
(Table 2).
The oral condition was assessed by four of the
61 institutions (7%). If so, the oral condition was
assessed at arrival and daily written records were
made of conditions and interventions. Lip moist-
ening was used by 35 of the institutions (57%).
While 44 institutions (72%) either cleaned the
teeth, mucosa or both, 17 (28%) did neither. The
teeth were cleaned with soft toothbrushes in 16
of the 21 (76%) identifiable procedures. Most
institutions used sterile sponges on locking twee-
zers or disposable oral swabs for cleaning the
mucosa.
Even though all procedures recommended that
the patients’ dentures were cleaned, only 20
(33%) actually did so.
In 22 of the institutions (36%), various concen-
trations of glycerol were used to lubricate the
mucosa, but only one institution (2%) reported
using a concentration below 30% (Table 2). How-
ever, three respondents pointed out that glycerol
was not used because of the danger of drying out
the mucous membranes. In 30 institutions (49%),
no lubricator was used.
A wide variety of oral care products was used
in the various procedures (Table 3). Thus, seven
Table 2 Open-ended items. Distribution of frequently occurring actions used within the procedures and compari-








Assessment of oral condition
Yes 4 (25) 0 (0) 4 (7) 0.004
No information 12 (75) 45 (100) 57 (93)
Lip moistening
Yes 11 (69) 24 (53) 35 (57) 0.38
Do not moisten/no information 5 (31) 21 (47) 26 (43)
Mouth cleaning procedures
Teeth only 1 (6) 1 (2) 2 (3) 1.00a
Mucosa only 3 (19) 12 (27) 15 (25)
Teeth and mucosa 8 (50) 19 (42) 27 (44)
Do not clean/no information 4 (25) 13 (29) 17 (28)
Cleaning dentures
Yes 5 (31) 15 (33) 20 (33) 1.00
No information 11 (69) 30 (67) 41 (67)
Use of lubricator
Glycerol ≤ 30% 0 (0) 1 (2) 1 (2) 0.57b
Glycerol > 30% 1 (6) 5 (11) 6 (10)
Glycerol unspecified 1 (6) 14 (31) 15 (24)
Other than glycerol 5 (31) 4 (9) 9 (15)
Do not use lubricator 9 (56) 21 (37) 30 (49)
aIn the analysis, the variables ‘Teeth only’, ‘Mucosa only’ and ‘Teeth and mucosa’ are combined into one category
defined as ‘Cleaning procedure’.
bIn the analysis, all glycerol concentrations and lubricator other than glycerol are combined into one category
defined as ‘Use lubricator’.
© 2015 John Wiley & Sons A/S and The Gerodontology Association. Published by John Wiley & Sons Ltd
4 S. F. Kvalheim et al.
different products or combinations of products
were used for lubricating lips, three for cleaning
teeth, 12 for cleaning mucosa and 16 for lubricat-
ing mucosa. In addition to the widespread use of
glycerol mentioned above, various concentrations
of chlorhexidine were frequently used. Even par-
acetamol was used in various mixtures with xylo-
caine and/or cream.
Authorship of the procedures. In 11 of the 13 hospi-
tals (85%), the procedures had been authored by
nurses and in two (15%) by physicians. Similarly,
the procedures were authored by nurses in 16 of
the 33 nursing homes (48%) and in one case
(3%) by a physician. The nursing homes differed
from the hospitals in that the procedures had also
been authored by the public dental service in 10
of them (30%), copied from textbooks in four
(12%) and written by others in two (6%).
Oral problems for patients and treating personnel. In
regard to the question of problems experienced by
the patient, three of the 16 hospitals (19%) and
21 of the 45 nursing homes (47%) failed to
respond. Of the responding 37 institutions, some
mentioned more than one problem. Accordingly,
the percentages exceed 100 in sum. A total of 67
responses were recorded.
The most frequent problem was dry mouth,
which was reported by 17 of the 37 responding
institutions (46%), and with descending fre-
quency plaque, food particles and fungus infec-
tions, each reported by 7 (19%); sores and scab,
each reported by 6 (16%); viscous ropy saliva
and chapped lips, each reported by 5 (14%);
reduced appetite and pain, each reported by 4
(11%); and dysphagia, halitosis, coughing and
problems using dentures, each reported by 1
(3%).
The problems experienced by the personnel
were lack of knowledge/experience/routine, which
was experienced by 16 of the 37 responding insti-
tutions (43%), lack of patient cooperation by 14
(38%), that oral problems were not prioritised by
8 (22%), difficult access to the mouth by 4 (11%),
lack of resources by 3 (8%) and retching by one
(3%).
Comparisons
There were no significant statistical differences
between hospitals and nursing institutions for any
of the variables in Table 1. The only difference
between the institutions was whether or not the
oral condition of the terminal patients was
assessed on arrival (Table 2). Whereas such an
assessment was made by four of the 16 hospi-
tals (25%), none of the nursing institutions did
so, showing a highly significant difference
(p = 0.004).
Table 3 Products used in oral care procedures.












a and water 1:3
H2O2 3%
Chlorhexidine, undiluted
Chlorhexidine and water 1:2
















Paracetamol mixture and cream










cCarbonated water containing salts and minerals.
dSterile water with baking soda, mycostatin and chlorhexidine.
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A comparison between those institutions that did
have procedures for end-of-life palliative oral care
and those that did not showed no significant differ-
ence in reported level of knowledge (p = 0.104)
nor in recognising that the oral condition repre-
sents a significant problem (p = 0.350).
Discussion
In this investigation, an attempt was made to
assure that the results could be regarded as repre-
sentative for the way palliative oral care for end-
of-life patients is implemented in Norwegian
health institutions. The method of selection
assured geographical distribution throughout the
country, in that all counties were represented.
Moreover, the institutions within each county
were randomly selected. The relatively high num-
ber of institutions selected (76), the high response
rate (84% for the hospitals and 79% for the nurs-
ing homes) and the fact that the procedures to a
large extent were dispatched as written proce-
dures also testify to the validity of the results. The
fact that no responder felt the need for further
clarification points in the same direction.
However, the fact that only the charge nurse or
deputy completed the questionnaire might be
considered a limitation, primarily because there is
no guarantee that the reported procedures were
actually implemented in the wards. A charge
nurse has mainly administrative responsibilities
and does not normally inspect or participate in
patient care. Consequently, the results of this
investigation only reflect what the charge nurses
or deputies report. On the other hand, the head
nurse of responding institutions that had current
procedures regarding palliative oral care for end-
of-life patients would no doubt report them.
Regardless, the above limitation does not
detract from the most surprising and disturbing
finding that one of four institutions had no proce-
dures at all in this respect. However, it cannot be
precluded that this result may in part be related
to the fact that interprofessional teams with spe-
cific responsibility for palliative care are only
occasionally established – typically in the larger
regional hospitals and in some hospices.
The procedures varied widely, both in terms of
choice of method, and especially in selection of
oral care products. It may be considered remark-
able that as many as 21 different methods for pal-
liative oral care were identified. Also, the use of
oral care products (Table 3) was sometimes con-
tradictory. As an example, glycerol solution was
used by 36% of the institutions for lubricating
mucosa. It is a matter of concern that 10% of the
institutions used glycerol at higher concentrations
than 30% (Table 2). If exceeding this concentra-
tion the product becomes hypertonic, its use will
have a desiccating effect19,23. This is contrary to a
major purpose of oral palliative care, which is to
prevent dehydration of the mucous membranes24,
and is especially important for patients with dry
mouths and mouth breathers, conditions common
in dying patients.
Also questionable was the use of chlorhexidine
for cleaning mucosa. It has been argued that this
product is well suited because of its antimicrobial
properties, which might reduce the risk of aspira-
tion pneumonia caused by oral bacteria25. On the
other hand, it has also been argued that chlorhex-
idine should not be used because it can cause
burning and drying of the mucous membranes
and may have an adverse effect on the normal
oral flora26.
In several of the procedures, a solution of
hydrogen peroxide was used (Table 3), probably
because of its expectorant effect27. In some proce-
dures, the concentration was unspecified; in
others, a 3% solution was used. This is a consid-
erably stronger solution than the 0.5% concentra-
tion recommended in the Oxford Textbook of
Palliative Medicine28. Even more peculiar was the
use of mixtures containing paracetamol (acetami-
nophen) used for lubricating mucosa. True, parac-
etamol is used for the relief of pain, however,
only if administered gastrointestinally; no effect
can be expected when applied on the mucosa.
‘D€usseldorf mixture’ contains an aqueous
solution of baking soda, mycostatin and chlorhex-
idine. The mixing ratios are, however, such,
that it is highly uncertain whether this has any
effect.
In addition to these products, the wide variety
of other substances specified in Table 3 indicates
much uncertainty among Norwegian health insti-
tutions in regard to palliative oral care for end-
of-life patients. This is corroborated by the present
findings that 37% of them stated that they had
insufficient knowledge of the subject and that
25% had no procedures at all. To some extent,
this uncertainty may be explained by the fact that
there is little evidence in the literature that one
oral care agent is better than another20. Similar
uncertainty has been observed in other coun-
tries29,30.
It has been shown that significant and consis-
tent improvement of oral health can be obtained
using specific protocols13. However, the fact that
only 52% of the presently studied institutions
© 2015 John Wiley & Sons A/S and The Gerodontology Association. Published by John Wiley & Sons Ltd
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recognised that oral problems were of significant
importance (Table 1) and that 22% reported that
oral problems were not prioritised indicates that
palliative oral care is not highly appreciated in
Norway. That none of the nursing homes assessed
the oral condition as opposed to 25% of the hos-
pitals, although statistically significant, should
probably not be attributed much importance.
Most likely, when patients are admitted to a nurs-
ing home, they would already be assessed by a
hospital.
One might perhaps expect that institutions that
had procedures for palliative oral care were more
knowledgeable than those that did not. Confus-
ingly, this hypothesis was not corroborated in the
present study, neither in terms of their reported
level of knowledge nor their recognition of the
oral condition as a significant problem. These
findings are all the more surprising in view of the
fact that death in Norway has become largely in-
stitutionalised and specific, and/or individualised
procedures related to all terminal diseases have
been developed with the intention of reducing
the physical and mental strain that terminal ill-
nesses entail.
The confusion regarding palliative oral care
exhibited by Norwegian health institutions is,
however, not a local phenomenon. The same
degree of confusion appears to be present in other
European countries such as the United Kingdom
(A. Davies, personal communication), Sweden31
and Holland32 and is probably mainly caused by
a lack of evidence-based effective procedures,
which are indeed conspicuously absent in the
literature33,34. In fact, to the best knowledge of
the authors, experimental studies pertaining to
the efficacy of palliative oral care procedures and
products are wanting. This demonstrates the
urgent need for research in these matters so that
evidence-based national and international proce-
dures can be established.
Conclusion
The results of the present study indicate that
the practices regarding palliative oral care for
end-of-life patients in Norwegian institutions are
both unstructured and haphazard. Some termi-
nal patients do not receive adequate oral care as
no procedures to that effect exist. Sufficient
funding for establishing interprofessional oral
health care teams and improved oral care train-
ing of nurses and other front-line caregivers
within this field is necessary. The empirical data,
on which institutions base their procedures, are
for the most part not evidence based, indicating
that the scientific basis for specifying methods
and oral care products is inadequate. There are
obvious methodological problems with research
in this area, but these should be overcome to
provide good care in a way that comforts the
dying.
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The majority of severely ill patients experience dry mouth. For institutionalized
patients, this condition is commonly treated using glycerol as a lubricant. However,
because of its possibly desiccating effect, some countries do not advocate the use of
glycerol. This study aimed to investigate dose-dependent effects of glycerol on
homeostasis and tissue integrity of in vitro-reconstructed normal human buccal
mucosa (RNHBM). Primary keratinocytes and fibroblasts were isolated and
expanded from biopsies of mucosa from eight healthy volunteers. Ninety-six sam-
ples of RNHBM were prepared and exposed for 24 h to 17%, 42.5%, or 85% glyc-
erol, or to distilled H2O (control). Sections were stained with haematoxylin and
eosin (H&E) to evaluate epithelial thickness or used for immunohistochemistry to
measure expression of Ki67 (proliferation), cleaved caspase-3 (apoptosis), and
E-cadherin (tissue-integrity). Positive cells and cell layers, as detected by immunohis-
tochemistry, were counted. Epithelial thickness, proliferation, and apoptosis were
significantly increased by exposure to 42.5% and 85% glycerol. No significant dif-
ferences in apoptosis or proliferation were found between controls and RNHBM
exposed to 17% glycerol. E-cadherin expression was not significantly affected by
exposure to any of the concentrations of glycerol tested. This study shows that
glycerol affects tissue homeostasis, but not tissue integrity, of RNHBM at glycerol
concentrations above 42.5%.
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A majority of patients in palliative care have problems
with dry mouth caused by medication, mental status,
or as a direct result of the mortal condition (1, 2). Dry
mouth causes a variety of problems that commonly
affect the disease negatively and contribute to reduced
quality of life in the patient’s last stage of life. Lack of
saliva in severely ill patients often leads to infections of
the mouth and throat, discomfort, pain, dysphagia,
speech problems, and loss of appetite (3, 4).
A large number of artificial saliva products are com-
mercially available. In recent years, there has been
increasing focus on saliva research, mainly based on
products containing nanoparticles and stem cells (5). So
far, no one has succeeded in making artificial saliva
that mimics the complexity of natural saliva (6, 7).
Glycerol is a simple polyol compound. As a result of
its chemical structure, it has a large number of different
applications: as a sweetening agent; in cosmetics pro-
duction; as a constituent of soap, candy, and antifreeze;
and in the production of different medications. Glyc-
erol is considered non-toxic and safe. The ability to
attract water from its surroundings is the basis for its
use as a humectant in moisturizers. The hygroscopic
properties of glycerol depend on its dilution in water
and on the relative humidity of the surrounding air,
which is related to temperature (8).
In Norway and many other countries, glycerol
diluted in water in different concentrations, from 17%
to the pure form of about 85%, is the most commonly
applied oral moisturizer in palliative care patients (9).
Being cheap, easily available, and easy to apply, glyc-
erol is used for the purpose of oral mucosa lubrication
in many other countries, whereas in some countries,
including USA, the Netherlands, Great Britain, and
Singapore, glycerol applied as an oral moisturizer is
not recommended because of its hygroscopic properties,
which may cause desiccation (10). The hygroscopic
properties of glycerol are well known. Nevertheless, the
literature is sparse when it comes to documenting the
effect of glycerol at molecular and cellular levels. Its
effects on oral mucosa have not yet been systematically
investigated and documentation on its biological effects
is currently lacking.
Oral epithelium is a stratified squamous epithelium
consisting of cells tightly attached to each other and
arranged in a number of distinct cell layers. Like epi-
dermis and the lining of the gastrointestinal tract, its
normal structure and function require a balance to be
maintained between continuous cell loss at the epithe-
lial surface and cell proliferation at the basal cell layer
(homeostasis), as well as competent cell-to-cell adhesion
(tissue integrity) (11, 12). Among constituent structural
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molecules that assemble in order to ensure adequate
epithelial cell-to-cell adhesion, cadherin/catenin-based
anchoring junctions organize and tether microfilaments
to maintain cell-adhesive properties (13, 14). Both
in vitro and in vivo studies have suggested E-cadherin
as a key player in maintaining cell-to-cell adhesion and
tissue integrity. The absence of E-cadherin leads to per-
meable tight junctions and to altered epithelial tissue
integrity and resistance (15). Blocking E-cadherin
in vitro inhibits tight junctions in simple epithelia (16),
as does genetic loss of epidermal E-cadherin (17).
The objective of this study was to investigate dose-
dependent effects of glycerol on homeostasis (cell
proliferation and apoptosis) and tissue integrity
(E-cadherin expression) of in vitro-reconstructed nor-
mal human buccal mucosa (RNHBM). In vitro-
RNHBM was chosen as an experimental model
because of its similarity to native normal human buc-
cal mucosa (18, 19). Reconstructed normal human
buccal mucosa displays a well-differentiated stratified
squamous epithelium expressing various markers of
proliferation, differentiation, and apoptosis in a pat-
tern similar to that of native buccal epithelium, mim-
icking closely its architecture and homeostasis (19).
Biopsies of 0.5 cm2 enable the production (cultivation)
of RNHBMs from which it possible to produce a
large number of parallel tissue sections. These permit
the study of the effects of reagents on tissue replicates
derived from the same patient. Using these tissues, we
were able to perform a standardized study, avoiding
direct involvement of patients or experimental animals.
The same kind of RNHBM samples have been used
previously to study homeostasis and tissue integrity
under the influence of khat (20) and sodium lauryl
sulphate (SLS) (21).
Material and methods
Tissue material from human donors
Eight biopsies of normal human mucosa with an approxi-
mate size of 0.5 cm2 were obtained from superfluous buc-
cal mucosa of patients undergoing surgical removal of a
third molar (Fig. 1A). The indication for this treatment
was partially erupted teeth. Only young healthy adults
with no subjective or clinical sign of local inflammation at
the time of surgery were included. All patients gave
informed consent for use of their tissue samples.
For immunohistochemistry and histomorphometry anal-
yses, only RNHBM samples with a continuous epithelium
consisting of at least five cell layers were included. Samples
were placed in transport medium (Fig. 1B): Dulbecco’s
modified Eagle’s medium (DMEM; Sigma, St Louis, MO,
USA) containing 2% antibiotics-antimycotics (Gibco-
BRL, Grand Island, NY, USA). The Regional Committee
of Medical Ethics in Research approved the project (REK
approval: 2015/1851).
Primary cell isolation
The biopsy was cleaned with PBS (Gibco-BRL) and then
washed twice with fresh transport medium. In order to
separate epithelium from connective tissue, the tissues were
transferred to dispase solution [20 mg of dispase (Gibco-
BRL) in 7.5 ml of DMEM/2% antibiotics-antimycotics]
and kept at 4°C for 24 h. The following day the two tissue
layers (epithelium and connective tissue) could be sepa-










Fig. 1. Illustration of the key steps for reconstruction and exposure of the reconstructed normal human buccal mucosa
(RNHBM) samples to glycerol. (A) Donor site. (B) Transfer of tissue to transport medium. (C) Subculture of keratinocytes (C1)
and fibroblasts (C2). (D) Seeding keratinocytes on the fibroblast biomatrix. (E) Lifting the RNHBM samples to grids. (F) Adding
medium during maturation. (G) Exposing. (H) Harvesting the RNHBM samples.
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Fig. 1C1) were isolated through a combination of enzy-
matic digestion (trypsin EDTA 9 10; Sigma) and mechan-
ical separation of cells, and then cultured in keratinocyte
serum-free medium (KSFM; Gibco-BRL) supplemented
with 1 ng ml1 of epidermal growth factor (EGF human
recombinant; Gibco-BRL), 25 lg ml1 of bovine pituitary
extract (BPE; Gibco-BRL), 20 lg ml1 of L-glutamine,
and 1% AB/AM (100 U ml1 of penicillin, 100 lg ml1
of streptomycin, and 0.25 lg ml1 of amphotericin B;
Gibco-BRL). Primary buccal connective tissue cells
(fibroblasts; Fig. 1C2) were isolated using an explant tech-
nique and cultured in DMEM supplemented with 10%
fetal bovine serum (FBS; Sigma), 20 lg ml1 of L-gluta-
mine, and 1% AB/AM (100 U ml1 of penicillin,
100 lg ml1 of streptomycin, and 0.25 lg ml1 of ampho-
tericin B). All cells were used in their third to fourth pas-
sages (split ratio of 1:4), at a viability of more than 80%,
kept in a humidified atmosphere at 37°C, and supple-
mented with 5% CO2.
Preparation of RNHBM samples
From each donor’s biopsy, RNHBM samples were con-
structed when sufficient numbers of the two cell types –
fibroblasts and keratinocytes – were achieved (Fig. 1D).
The connective tissue equivalent was first reconstructed by
mixing 350,000 fibroblasts per ml of collagen matrix: a mix-
ture of collagen type I (REF354236, 3.81 mg ml1,
LOT5061002; NAME OF COMPANY, Corning, NY,
USA), reconstitution buffer, pH 8.15 [2.2 g of sodium
bicarbonate (NaHCO3), 0.6 g of sodium hydroxide
(NaOH), 4.766 g of HEPES, in 100 ml of deionized H2O
(dH2O)], and DMEM (Sigma) (19). A total of 400,000 ker-
atinocytes in 1 ml of KSFM were seeded on top of each
collagen matrix the following day, set as day 1. After 24 h,
on day 2 of co-culture, the matrix, consisting of the two cell
layers, was transferred to a metal grid placed in a well of a
six-well plate (Fig. 1E). Three millilitres of fresh
organotypic medium (OT-FAD) – DMEM/HAM’s F12:
3/1 with 0.4 lg ml1 of hydrocortisone, 5 lg ml1 of insu-
lin, 20 lg ml1 of transferrin, and 50 lg ml1 of L-ascor-
bic acid (all from Sigma) – was added underneath the
metal grid along with 700 ll of conditioned medium.
Throughout the experiment, care was taken to protect the
RNHBM samples from spill of the medium. The
RNHBM samples were allowed to mature for 9 days.
Within this period, 2 ml of the medium was changed
every second day (Fig. 1F). Emphasis was placed on
acquiring enough cells to produce at least 12 RNHBM
samples from each donor in order to obtain three samples
for each of the three concentrations and the control. The
number of RNHBM samples from each donor varied
from 14 to 22. From all eight donors, a total of 134
RNHBM samples were cultivated. Of these RNHBM sam-
ples, 10 were either destroyed during cultivation or were
not of satisfactory quality –six RNHBM samples turned
upside down when lifted from the well-plate over to the
grid and four RNHBM samples did not exhibit a suffi-
cient number of keratinocytes. Hence, 124 RNHBM sam-
ples remained for further analyses. The RNHBM samples
from each donor were allocated to one of the three con-
centrations or to dH2O as a control (Table 1).
Exposure procedures to glycerol
On day 9 of co-culture (day 10 of culture and day 6 at the
air–liquid interface), RNHBM samples were exposed to
glycerol (batch no 17A121; Sanivo Pharma, Oslo, Norway)
diluted in water to three different concentrations (Fig. 1G).
At that time, a full-thickness, well-maturated buccal epithe-
lium was formed. Based on an exploratory study (9) clini-
cally relevant concentrations of 17%, 42.5% and 85% were
chosen for exposure of RNHBM samples. A two-step pro-
cedure was used to decrease the surface tension and to
obtain a more even exposure of the tissue surface without
allowing any glycerol to spill into the culture medium
Table 1
Effect of exposure to water (control) and different glycerol concentrations on epithelial thickness, homeostasis (cell proliferation and
apoptosis), and tissue integrity in in vitro reconstructed normal human buccal mucosa
Variable No. of sections P-value ICC (95% CI)
Epithelial thickness (lm) 96
Control (dH2O) 88.85 (81.57–96.14) 28 <0.001
§ 0.03 (0.01–0.12)
17% glycerol 75.60 (68.81–82.39) 26 <0.001
42.5% glycerol 110.09 (102.71–117.46) 20 <0.001
85% glycerol 144.24 (137.10–151.37) 22 <0.001
Proliferation* (positive cells per 1000 lm) 71
Control (dH2O) 5.85 (2.60–9.09) 17 <0.001
§ 0.52 (0.23–0.78)
17% glycerol 4.67 (1.46–7.90) 18 0.303
42.5% glycerol 8.86 (5.64–12.08) 18 0.008
85% glycerol 8.35 (5.14–11.57) 18 0.027
Apoptosis† (positive cells per 1000 lm) 71
Control (dH2O) 1.05 (0.081–2.02) 17 <0.001
§ 0.23 (0.06–0.58)
17% glycerol 1.21 (0.26–2.17) 18 0.746
42.5% glycerol 2.23 (1.27–3.18) 18 0.020
85% glycerol 5.59 (4.64–6.55) 18 <0.001
Tissue integrity‡ (positive cell layers/negative cell layers) 71
Control (dH2O) 0.73 (0.61–0.84) 17 0.160
§ 0.28 (0.08–0.61)
17% glycerol 0.61 (0.49–0.73) 18 0.047
42.5% glycerol 0.67 (0.56–0.79) 18 0.367
85% glycerol 0.72 (0.61–0.84) 18 0.983
*Ki-67; †Cleaved caspase 3; ‡E-cadherin; §Test of homogeneity; dH2O, distilled H2O; ICC, intraclass correlation coefficient.
Glycerol’s effect on an oral mucosa model 3
below. Initially, 60 ll of glycerol was placed on the
RNHBM sample surface and sucked off. Immediately
afterwards, a smaller volume (30 ll) of glycerol was
applied, making a thin continuous film, and left on the tis-
sue surface for 24 h. The same procedure was repeated for
the controls, but with dH2O. Exposed cultures were har-
vested on day 10 of the co-culture and immediately trans-
ferred to 4% buffered formalin, dehydrated, and embedded
in paraffin (Fig. 1H). All experiments were run in parallel
for the full range of glycerol concentrations and control
(dH2O), and the process was repeated for the RNHBM
samples from each donor. Humidity in the incubator was
measured throughout the whole procedure (Wood’s
hygrometer p-cv8005 Termohygrometer, Guelph, ON,
Canada) and maintained at 89%–95%. All RNHBM sam-
ples were kept at the same middle level in the incubator.
Evaluation of the 124 sections
When evaluating the 124 sections in a light microscope, it
was considered that 28 RNHBM samples from two of the
donors had not developed an adequate epithelial layer.
These samples were therefore excluded from further analy-
ses. One section from each of the remaining 96 RNHBM
samples was used for histomorphometry. Regarding
immunohistochemistry, because of extremely resource-
demanding procedures, a randomized selection of three
RNHBM samples from each donor/concentration was
used. For technical reasons, only two controls were used
from one donor (Table 1, Figs 1 and 2).
Immunohistochemistry
For immunohistochemistry, 5-lm-thick formalin-fixed,
paraffin-embedded tissue sections were cut and deparaf-
finized in xylene, hydrated through a graded alcohol series,
and then rehydrated in dH2O. For epitope retrieval, the tis-
sue sections were microwave-treated in 10 mM citrate buf-
fer, pH 6 (Dako, Glostrup, Denmark) or Tris/EDTA pH 9
(Dako) for 7 min at 950 W and then for 15 min at 350 W.
After cooling for 20 min at room temperature, the speci-
mens were incubated with primary antibodies in a humidi-
fied chamber at room temperature for 60 min. The markers
used for cell proliferation, apoptosis, and tissue integrity
Fig. 2. Flow chart detailing the steps for construction of reconstructed normal human buccal mucosa (RNHBM) samples, and
different stages in the histomorphometry and immunohistochemistry (IHC) analyses. dH2O, distilled H2O; Gly, glycerol.
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were Ki-67 (M7240, Clone MIB-1, 1:300; Dako), cleaved
caspase-3 (M3612, Clone NCH-38, 1:600; Dako), and
E-cadherin (D175, Clone 5A1E, 1:3,000; Dako), respec-
tively. The secondary antibodies were Dako REAL EnVi-
sion Detection System, Peroxidase/DAB+ and Rabbit/
Mouse. Specimens incubated with antibody diluent only
(Dako), or isotype-matched antibody (Dako) instead of pri-
mary antibody, were used as negative controls. As positive
controls, either normal mucosa or RNHBM samples
exposed to SLS from a previously published study (21) were
used.
Evaluation of samples
Histomorphometry: Tissue sections (5 lm thick) from
formalin-fixed tissues were cut, stained with haematoxylin
& eosin (H&E) (Dako), and evaluated morphologically
under a light microscope (Nikon Eclipse 80i; Nikon
Instruments, Amsterdam, the Netherlands) at 200-fold
magnification on six consecutive fields situated 200 lm
apart. The outer 500 lm of the RNHBM samples was
omitted from the measurements. Total epithelial thickness
was measured as the distance from the surface of the
epithelium to the epithelial tissue–connective tissue equiva-
lent interface on a line perpendicular to the epithelial tis-
sue–connective tissue equivalent interface.
Homeostasis (cell proliferation and apoptosis) and tissue
integrity: To calculate the ratio of proliferating cells, the
number of Ki-67-positive cells was determined in the basal
and suprabasal cell layers, under a light microscope at
400-fold magnification. The average percentage of positive
cells per 1,000 lm was counted for the whole length of the
section, apart from the outermost 500 lm of the section.
The ratio between apoptotic cells and the number of
cleaved caspase-3-positive cells was obtained following the
same procedure as described for Ki-67. Epithelial cell lay-
ers with cells expressing E-cadherin were counted and
compared with non-exposed controls.
All measurements were made by the operator who was
blinded to the exposure allocations.
Statistical analysis
Data are presented as mean and 95% CI. For comparison
of the parameters across the different concentrations of
glycerol, linear mixed effects models were applied. In these
models, for each outcome, concentration was entered as a
categorical fixed effect. Donor was included and controlled
for in the model as a random effect accounting for the
possible correlation between samples from the same donor.
By including donor as a random effect, intraclass correla-
tions (ICCs) for correlation of the measures from the same
donor, for each of the parameters, can be calculated. An
ICC close to 1 implies that samples from the same donor
are highly correlated, while an ICC close to 0 implies that
the samples can be considered as independent. The main
results, based on the mixed models, were presented as esti-
mated marginal mean values and mean differences, with
95% CI. All statistical analyses were performed using the
statistical package STATA version 15 (Stata, College Sta-
tion, TX, USA). Values of P <0.05 were considered statis-
tically significant. A likelihood ratio test was used to test
for homogeneity of the categories of the variable for each
outcome.
Results
Histomorphometric evaluation of the epithelial
compartment in reconstructed tissues
Control RNHBM (i.e. tissues exposed to dH2O only)
displayed a well-differentiated, non-keratinized stratified
squamous epithelium with an average epithelial thick-
ness of 88.85 (95% CI: 81.57–96.14) lm. Exposure to
42.5% and 85% glycerol induced a significant increase
in epithelial thickness (P < 0.001 and P < 0.001, respec-
tively), whereas exposure to 17% glycerol induced a sig-
nificant decrease in epithelial thickness (P < 0.001). No
significant change in epithelial differentiation could be
observed on H&E-stained sections at these higher glyc-
erol concentrations. However, apoptotic bodies were
frequently observed within the spinous cell layer at
42.5% and 85% glycerol, in contrast to tissues exposed
to 17% glycerol and dH2O (control). The ICC for mea-
sures of epithelial thickness was 0.03 (Table 1, Fig. 3).
Distribution and quantification of cell proliferation
(determined by measuring expression of Ki-67)
Cell proliferation was most prominent along the basal
cell layer and in the lower cell layers; and the superficial
cell layers displayed no proliferation, either in controls
or in exposed tissues. Exposure to the low concentration
Fig. 3. Haematoxylin and eosin staining of representative
three-dimensional (3D) reconstructed oral buccal mucosal tis-
sues exposed to various concentrations of glycerol. Changes
in epithelial thickness are shown (original magnification 2009;
scale bar = 50 lm). In the bar chart, data are presented as
mean  SD, and statistically significant differences (P <0.05)
are marked with *.
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of glycerol (17%) did not induce significant changes in
epithelial cell proliferation (as assessed by counting the
number of Ki-67-positive cells per 1,000 lm; P = 0.30)
when compared with controls. For the two higher con-
centrations of glycerol (42.5% and 85%), epithelial cell
proliferation increased significantly (P = 0.008 and
P = 0.027, respectively). The ICC for counts of Ki-67-
positive cells was 0.52 (Table 1, Fig. 4).
Distribution and quantification of apoptosis
(determined by measuring cleaved caspase-3)
The cleaved caspase-3 positively stained cells (apoptotic
cells) were most frequent in the superficial cell layers in
both control and exposed tissues. Exposure to the low
concentration of glycerol (17%) did not induce a signif-
icant increase in the number of cleaved caspase-3 posi-
tively stained cells per 1,000 lm when compared with
controls (P = 0.75). For the two higher concentrations
of glycerol (42.5% and 85%), the number of apoptotic
cells increased significantly (P = 0.020 and P = 0.001,
respectively). The ICC for the counts of apoptotic cells
was 0.23 (Table 1, Fig. 5).
Evaluation of tissue integrity (determined by
measuring expression of E-cadherin)
The E-cadherin-positive cell layers formed a coherent
belt from the basal cell layer to the stratum
spinosum, both in controls and exposed tissues. Anal-
ysis of tissue integrity, evaluated as the relative num-
ber of E-cadherin-positive cell layers, showed a
borderline significance (P = 0.047) between controls
and tissues exposed to 17% glycerol. However,
between controls and tissues exposed to glycerol at
concentrations of 42.5% and 85%, there was no sig-
nificant difference (P = 0.37 and P = 0.98, respec-
tively). Test of homogeneity showed no overall
statistically significant differences in the relative num-
ber of E-cadherin-positive cell layers (P = 0.16)
between tissues exposed to the different glycerol con-
centrations. The ICC for the relative number of E-
cadherin-positive cell layers was 0.28 (Table 1,
Fig. 6).
Discussion
In the present study, we observed that glycerol con-
centrations of 42.5% and 85% induced an increase
of apoptosis in RNHBM, which was visualized by
immunohistochemistry using antibody detecting
cleaved caspase-3. Cleaved caspase-3 was chosen as a
marker for apoptotic cell death because it was shown
in previous studies to be an easy, sensitive, and reli-
able method for detecting and quantifying apoptosis,
compared with alternative methods such as the TdT-
mediated biotin–dUTP nick-end labelling (TUNEL)
Fig. 4. Immunohistochemical staining of sections of represen-
tative three-dimensional (3D) reconstructed oral buccal muco-
sal tissues exposed to various concentrations of glycerol.
Sections were stained for Ki-67, indicative of cell proliferation
(original magnification 2009; scale bar = 100 lm). The bar
chart shows quantification of cell proliferation, given as num-
ber of Ki-67-positive cells per 1000 lm length of epithelium–
matrix interface. Data are presented as mean  SD, and sta-
tistically significant differences (P <0.05) are marked with *.
Fig. 5. Immunohistochemical staining of sections of represen-
tative three-dimensional (3D) reconstructed oral buccal muco-
sal tissues exposed to various concentrations of glycerol.
Sections were stained for cleaved caspase-3, indicative of
apoptosis (original magnification 2009; scale bar 100 lm).
The bar chart shows apoptosis, given as number of cleaved
caspase-3-positive cells per 1000 lm length of epithelium–ma-
trix interface. Data are presented as mean  SD, and statisti-
cally significant differences (P <0.05) are marked with *.
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technique (22). The fact that an increase in apoptosis
of individual cells is observed with exposure to glyc-
erol indicates a certain toxic effect of glycerol at
higher concentrations. The count of Ki-67-positive
cells per 1,000 lm showed an increase in cell prolifer-
ation at the same high concentrations, indicating that
glycerol is able to trigger a tissue reaction. The stim-
ulation of cell proliferation is most probably a conse-
quence and a response of epithelial tissue to the
increased apoptosis induced by glycerol at high con-
centrations, in an attempt to maintain tissue home-
ostasis. Epithelial tissues maintain their homeostasis
by balancing the continuous cell loss from desquama-
tion on the surface with proliferation of cells in the
basal cell layer. Therefore, increased proliferation, as
a result of increased cell loss, is actually a natural
response of a healthy epithelium in order to maintain
tissue homeostasis (23).
Of concern in this study is the fact that the increase
in cell proliferation was overbalancing apoptosis
induced by exposure to glycerol, as indicated by the
increase in epithelial thickness. For long-term exposure,
one might argue that the use of high concentrations of
glycerol could increase the risk of malignant transfor-
mation of the epithelium as it induces increased prolif-
eration and thus increases the risk of accumulating
DNA errors with each cellular replication. Neverthe-
less, the increased risk of glycerol exposure should be
seen in a clinical context and with regard to the time
perspective in palliative care patients. A possible effect
of altered tissue integrity and changes in barrier func-
tion would have been more severe and more unfortu-
nate with regard to penetration of pathogens. Such an
effect does not seem to be present. This study shows
that glycerol does not affect tissue differentiation or tis-
sue integrity, as assessed by histological assessment of
H&E-stained slides and immunostaining to visualize
E-cadherin, a cell-to-cell adhesion molecule. The
expression of E-cadherin was not changed by exposure
to high concentrations of glycerol, indicating that the
cell-to-cell contacts were not altered, indirectly suggest-
ing a maintained barrier function. This is in contrast to
the effects observed following exposure to SLS, in
which E-cadherin expression was reduced and tissue
integrity disrupted, as previously shown (21).
Using the mixed effects model, reporting ICC, we
have also demonstrated that there are differences in the
correlation between samples for the different parame-
ters reported in this study. For epithelial thickness,
each sample can be considered to be independent, even
if they come from a limited number of donors. How-
ever, proliferation samples from the same donor are
clearly dependent, and this has to be taken into consid-
eration when interpreting the statistical analyses.
The RNHBM model has been chosen for its advan-
tages in mimicking the native tissue, as mentioned in
the Introduction. However, the use of an in vitro
model obviously has some limitations. One may ques-
tion whether it is appropriate to use healthy gingiva
from young people, as the palliative care patients on
whom glycerol is applied as a moisturizer are sick and
often old. However, it is important to point out that
the patient’s mucosa is most often not diseased or
damaged, and destruction and infection come as a
result of dryness. Using seriously ill patients as donors
for the RNHBM model would have been difficult for
practical, ethical, and sampling reasons. Most dying
patients are older than the donors in this study, and
may have a mild epithelial atrophy. Even considering
this aspect, in a previous study, the thickness of the
RNHBM was shown to be less than normal mucosa
(19). Another aspect that makes the RNHBM model
appropriate is that its surface is dry and might there-
fore adequately replicate the mucosal surface of
patients suffering from severe xerostomia. Formation
of the salivary mucosal pellicle is provided by salivary
mucins, probably mediated by hydrophobic interac-
tions to the epithelial cell surface (24). Terminally ill
patients with xerostomia often have an almost com-
pletely dry mucosal surface, perhaps even with the
absence of a salivary pellicle.
Glycerol absorbs moisture from the air, even if the
amount of moisture present is very small (8). As air
humidity affects glycerol, emphasis was placed on con-
trolling humidity in the incubator where the RNHBM
samples were kept during maturation and exposure.
The relative humidity in the incubator was 89%–95%,
but dropped when opened. This is higher than the nor-
mal relative humidity, which is usually between 30%
and 60%, and might have affected the glycerol
Fig. 6. Immunohistochemical staining of sections of represen-
tative three-dimensional (3D) reconstructed oral mucosal tis-
sues exposed to various concentrations of glycerol. Sections
were stained for E-cadherin, indicative of tissue integrity (origi-
nal magnification 2009; scale bar = 100 lm). The bar chart
shows tissue integrity, given as relative number of E-adherin-
positive cell layers. Data are presented as mean  SD, and
statistically significant differences (P <0.05) are marked with *.
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concentrations to become slightly lower than the base-
line concentrations.
Glycerol is one of the most commonly used raw
materials applied in cosmetics. It adds moisture by
attracting water from the deeper layers of the skin (25).
A similar system of water transport may be assumed
when glycerol is applied to oral mucosa. In healthy per-
sons, this would be of little consequence because of a
continuous supply of liquid. In terminally ill patients,
who are usually dehydrated (26), it seems likely that
the mucosa might then be further desiccated when high
concentrations of glycerol are used. However, it is not
known whether these patients manage to replace fluid
extracted from the underlying mucosa.
In conclusion, this study has shown that exposure of
RNHBM samples to glycerol at high concentrations
(42.5% and above) causes increased epithelial cell pro-
liferation and epithelial thickness, as well as increased
apoptosis compared with controls. Tissue integrity
shows a reduced number of E-cadherin-positive cell lay-
ers of borderline statistical significance in tissues
exposed to the lowest concentration of glycerol (17%),
but no difference compared with controls at higher con-
centrations. Overall, these findings indicate that the use
of glycerol is not harmful after short-term exposure but
might pose certain risks after long-term exposure.
Acknowledgements – The authors thanks Gunnvor Øijordsbakken
and Siren Hammer Østvold for technical assistance and personnel
from Tannteam dental clinic for patient logistics and handling the
tissues. This work was partly supported by the Research Council
of Norway through its Centres of Excellence funding scheme, pro-
ject number 223250 (DEC).
Conflicts of interest – None to declare.
References
1. FISCHER DJ, EPSTEIN JB, YAO Y, WILKIE DJ. Oral health con-
ditions affect functional and social activities of terminally ill
cancer patients. Support Care Cancer 2014; 22: 803–810.
2. SCULLY C. Drug effects on salivary glands: dry mouth. Oral
Dis 2003; 9: 165–176.
3. JOBBINS J, BAGG J, FINLAY IG, ADDY M, NEWCOMBE RG. Oral
and dental disease in terminally ill cancer patients. BMJ 1992;
304: 1612.
4. MANDEL ID. The functions of saliva. J Dent Res 1987; 66
(Spec No): 623–627.
5. PRINGLE S, VAN OS R, COPPES RP. Concise review: adult sali-
vary gland stem cells and a potential therapy for xerostomia.
Stem Cells 2013; 31: 613–619.
6. FURNESS S, WORTHINGTON HV, BRYAN G, BIRCHENOUGH S,
MCMILLAN R. Interventions for the management of dry
mouth: topical therapies. Cochrane Database Syst Rev 2011;
(12): CD008934.
7. KHO HS. Understanding of xerostomia and strategies for
the development of artificial saliva. Chin J Dent Res 2014; 17:
75–83.
8. MINER C, DALTON N. Glycerol. Baltimore, MD: The Waverly
Press Inc., 1953.
9. KVALHEIM SF, STRAND GV, HUSEBO BS, MARTHINUSSEN MC.
End-of-life palliative oral care in Norwegian health
institutions. An exploratory study. Gerodontology 2016; 33:
522–529.
10. HOLMES S. Nursing management of oral care in older
patients. Nurs Times 1996; 92: 37–39.
11. TEN NANCI A. Cate’s oral histology: development, structure,
and function, 7th edn. St. Louis, MO: Elsevier Health
Sciences, 2007.
12. MACARA IG, GUYER R, RICHARDSON G, HUO Y, AHMED SM.
Epithelial homeostasis. Curr Biol 2014; 24: R815–R825.
13. TIAN X, LIU Z, NIU B, ZHANG J, TAN TK, LEE SR, ZHAO Y,
HARRIS DC, ZHENG G. E-cadherin/beta-catenin complex and
the epithelial barrier. J Biomed Biotechnol 2011; 2011: 567305.
14. GUMBINER BM. Regulation of cadherin-mediated adhesion in
morphogenesis. Nat Rev Mol Cell Biol 2005; 6: 622–634.
15. MICHELS C, AGHDAM SY, NIESSEN CM. Cadherin-mediated
regulation of tight junctions in stratifying epithelia. Ann N Y
Acad Sci 2009; 1165: 163–168.
16. GUMBINER B, STEVENSON B, GRIMALDI A. The role of the cell
adhesion molecule uvomorulin in the formation and mainte-
nance of the epithelial junctional complex. J Cell Biol 1988;
107: 1575–1587.
17. TUNGGAL JA, HELFRICH I, SCHMITZ A, SCHWARZ H, GUNZEL
D, FROMM M, KEMLER R, KRIEG T, NIESSEN CM. E-cadherin
is essential for in vivo epidermal barrier function by regulat-
ing tight junctions. EMBO J 2005; 24: 1146–1156.
18. COSTEA DE, JOHANNESSEN AC, VINTERMYR OK. Fibroblast
control on epithelial differentiation is gradually lost during
in vitro tumor progression. Differentiation 2005; 73: 134–141.
19. COSTEA DE, LORO LL, DIMBA EA, VINTERMYR OK, JOHAN-
NESSEN AC. Crucial effects of fibroblasts and keratinocyte
growth factor on morphogenesis of reconstituted human oral
epithelium. J Invest Dermatol 2003; 121: 1479–1486.
20. LUKANDU OM, NEPPELBERG E, VINTERMYR OK, JOHANNESSEN
AC, COSTEA DE. Khat alters the phenotype of in vitro-recon-
structed human oral mucosa. J Dent Res 2010; 89: 270–275.
21. NEPPELBERG E, COSTEA DE, VINTERMYR OK, JOHANNESSEN
AC. Dual effects of sodium lauryl sulphate on human oral
epithelial structure. Exp Dermatol 2007; 16: 574–579.
22. DUAN WR, GARNER DS, WILLIAMS SD, FUNCKES-SHIPPY CL,
SPATH IS, BLOMME EA. Comparison of immunohistochemistry
for activated caspase-3 and cleaved cytokeratin 18 with the
TUNEL method for quantification of apoptosis in histologi-
cal sections of PC-3 subcutaneous xenografts. J Pathol 2003;
199: 221–228.
23. GUILLOT C, LECUIT T. Mechanics of epithelial tissue home-
ostasis and morphogenesis. Science 2013; 340: 1185–1189.
24. GIBBINS HL, YAKUBOV GE, PROCTOR GB, WILSON S, CARPEN-
TER GH. What interactions drive the salivary mucosal pellicle
formation? Colloids Surf B Biointerfaces 2014; 120: 184–192.
25. PAPPAS A. Lipids and skin health. New York: Springer, 2015;
318.
26. GOOD P, RICHARD R, SYRMIS W, JENKINS-MARSH S, STEPHENS
J. Medically assisted hydration for adult palliative care
patients. Cochrane Database Syst Rev 2014; (4): CD006273.
8 Kvalheim et al.
Appendix Study I, II and III 
 
Appendix I 






Spørreskjema om palliativt munnstell 
 
 
1) Sykehjem   Sykehus 
 
2) Har dere prosedyrer for munnstell for døende pasienter på deres institusjon? 
 
Ja  Nei  Vet ikke 
 














5) Føler du at man har tilstrekkelig kunnskap om dette emnet på deres institusjon? 
 
Ja  Nei  Vet ikke 
 
6) Opplever du at munnproblemer er et vesentlig problem for svært syke eller døende 
pasienter? 
 
Ja  Nei  Vet ikke 
 









Takk for hjelpen! 
 
Appendix II 
Informed Consent form, Study II 
II 
 
 In vitro studie på modell av oral slimhinne.  
Side 1 / 2 
 
FORESPØRSEL OM DELTAKELSE I FORSKNINGSPROSJEKTET 
Bruk av kunstig munnslimhinne for undersøkelse av opptak og reaksjon 
på midler brukt ved munnstell hos alvorlig syke eller døende personer  
Dette er et spørsmål til deg om å delta i et forskningsprosjekt. Studiens hensikt er å undersøke ulike 
fuktighetsgivende midler som benyttes i stell av kreftpasienter og døende pasienter i norske helseinstitusjoner. 
Du ble spurt å delta i denne studien fordi du er frisk og vi har behov for slimhinne fra friske pasienter. Fra 
slimhinnen dyrkes enkeltceller som brukes til å lage en slimhinnemodell, som munnpleiemidlene skal testes på. 
Forskningsansvarlig for prosjektet er Universitetet i Bergen og Helse Bergen HF. 
HVA INNEBÆRER PROSJEKTET? 
En liten vevsprøve (3-4 mm) av munnslimhinnen tas under din planlagte operasjon i munnhulen. Prøven tas i 
operasjonsområdet. Området vil da være godt bedøvet (uten behov for ekstra bedøvelse). Prøvetakingen vil 
ikke få noen spesiell betydning i forhold til hvordan sårområdet normalt gror etterpå. Prøven får tildelt et 
nummer i den videre behandlingen, slik at de som behandler prøvene gjør dette anonymt.  
Opplysninger som registreres om deg vil bli innhentet fra pasientjournalen ved behandlende klinikk (kjønn, 
alder, og eventuelle røykevaner). Formålet er å kontrollere at studieopplysningene stemmer overens med 
tilsvarende opplysninger i din journal. Alle som får innsyn har taushetsplikt.  
MULIGE FORDELER OG ULEMPER 
Metodene for vevsprøvetaking er klinisk etablerte, og det er utelukkende erfarne medarbeidere inkludert i 
studien. Vi ser ingen spesiell risiko eller ulempe ved å delta i prosjektet (ikke annen eller ekstra risiko enn det 
som er vanlig relatert til den aktuelle typen operasjon).  
FRIVILLIG DELTAKELSE OG MULIGHET FOR Å TREKKE SITT SAMTYKKE  
Det er frivillig å delta i prosjektet. Dersom du ønsker å delta, undertegner du samtykkeerklæringen på siste 
side. Du kan når som helst og uten å oppgi noen grunn trekke ditt samtykke. Dette vil ikke få konsekvenser for 
din videre behandling. Dersom du trekker deg fra prosjektet, kan du kreve å få slettet innsamlede prøver og 
opplysninger, med mindre opplysningene allerede er inngått i analyser eller brukt i vitenskapelige 
publikasjoner. Dersom du senere ønsker å trekke deg eller har spørsmål til prosjektet, kan du kontakte: 
Professor Daniela Elena Costea, daniela.costea@uib.no , tel. 55973228 eller mobiltlf. 483 52 677 eller 
stipendiat, Siri Kvalheim, Siri.Kvalheim@uib.no, tlf. 55586488 eller mobiltlf. 481 73 272. 
HVA SKJER MED OPPLYSNINGENE OM DEG?  
Opplysningene som registreres om deg skal kun brukes slik som beskrevet i hensikten med prosjektet. Du har 
rett til innsyn i hvilke opplysninger som er registrert om deg og rett til å få korrigert eventuelle feil i de 
opplysningene som er registrert. Du har også rett til å få innsyn i sikkerhetstiltakene ved behandling av 
opplysningene.  
Alle dine opplysninger og prøver vil bli behandlet anonymt; det vil si uten navn, fødselsnummer eller andre 
direkte gjenkjennende opplysninger. En kode knytter deg til dine opplysninger og prøver gjennom en 
navneliste. Det er kun autorisert personell knyttet til prosjektet som har adgang til navnelisten og som kan 
finne tilbake til deg. Det vil ikke være mulig å identifisere deg i resultater av studien når disse publiseres.  
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HVA SKJER MED PRØVER SOM BLIR TATT AV DEG OG INFORMASJON OM DEG?  
Biopsiprøvene som blir tatt og informasjonen utledet av dette materialet vil bli lagret i en forskningsbiobank 
ved Haukeland Universitetssykehus. Hvis du sier ja til å delta i studien, gir du også samtykke til at det biologiske 
materialet og analyseresultater inngår i biobanken NanoMunnslimhinne. Professor Daniela Elena Costea er 
ansvarshavende for forskningsbiobanken. Biobanken planlegges å vare til 2018. Etter dette vil materiale og 
opplysninger bli destruert og slettet etter interne retningslinjer. Biobanken opphører ved prosjektslutt. 
ØKONOMI  
Studien og biobanken er finansiert gjennom forskningsmidler fra EU og Universitet i Bergen. 
GODKJENNING 
Regional komité for medisinsk og helsefaglig forskningsetikk har vurdert prosjektet, og har gitt 
forhåndsgodkjenning (saksnr.2015/1851). 
Du har rett til å klage på behandlingen av dine opplysninger til Datatilsynet.  
KONTAKTOPPLYSNINGER 
Dersom du har spørsmål til studien, kan du ta kontakt med Professor Daniela Elena Costea, 
daniela.costea@uib.no , tel. 55973228 eller mobiltlf. 483 52 677 eller stipendiat, Siri Kvalheim, 
Siri.Kvalheim@uib.no, tlf. 55586488 eller mobiltlf. 481 73 272. 
 
JEG SAMTYKKER TIL Å DELTA I PROSJEKTET OG TIL AT MINE PERSONOPPLYSNINGER OG 
MITT BIOLOGISKE MATERIALE BRUKES SLIK DET ER BESKREVET 
 
 




 Deltakers navn med trykte bokstaver 
 
Jeg bekrefter å ha gitt informasjon om prosjektet 
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